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Development and Evaluation of New Generation Vaccines 
Against Bovine Respiratory Syncytial Virus 
Abstract 
Bovine respiratory syncytial virus (BRSV) is a major cause of respiratory disease in 
cattle worldwide. Improved BRSV vaccines are needed, with better efficacy and longer 
duration of protection, in particular when used in calves with specific maternally 
derived antibodies (MDA). New generation BRSV vaccines should also be DIVA 
compliant, and thus allow continued seromonitoring in vaccinated herds, including 
continuous evaluation of vaccine safety and efficacy. 
In this thesis work, classic BRSV immunostimulating complexes (BRSV-ISCOMs) 
were shown to overcome inhibition by specific MDA, and induce a high level of 
protection, probably mediated by strong humoral and Th1 type T cell responses. 
Characterization of proteins in BRSV-ISCOMs was performed to facilitate future 
standardization or improvement of BRSV-ISCOMs, and to serve as a basis to design 
efficient subunit vaccines (SU). SU consisted of recombinant human RSV (HRSV) 
proteins P, M2-1 and N nanorings with epitopes from BRSV proteins F and G. 
Three DIVA-compatible vaccines, all omitting the SH protein, were evaluated: two 
vaccines formulated using SU, adjuvanted by either Montanide ISA71VG (SUMont) or 
AbISCO-300 (SUAbis); and ∆SHrBRSV, a live recombinant BRSV with deleted SH 
gene. The safety, immunogenicity and protective efficacy of SUMont, SUAbis and 
∆SHrBRSV were compared in calves with specific MDA in a BRSV infection model 
with high clinical expression, which was also developed in this thesis work. 
Both ∆SHrBRSV and SUMont induced protection against BRSV infection, 
seemingly by activating different immunological pathways. ∆SHrBRSV induced 
almost complete clinical and virological protection, which appeared to rely mainly on 
mucosal IgA and systemic neutralizing antibodies directed against viral surface 
proteins, and T cell priming in the airways. SUMont induced a good level of protection, 
which appeared to be mediated by HRSV/BRSV cross-reactive specific T cells. 
SUAbis induced limited protection from BRSV challenge. 
The three vaccines BRSV-ISCOMs, ∆SHrBRSV and SUMont, individually 
identified as promising vaccine candidates, are described and discussed in this thesis, 
including possibilities to improve their immunogenicity and protective efficacy, and to 
further investigate induced immunity and DIVA compliancy. 
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1 Introduction 
1.1 Background 
Bovine respiratory syncytial virus (BRSV) is a major cause of respiratory 
disease in cattle, and an important cause of enzootic pneumonia in calves 
worldwide (Valarcher & Taylor 2007). 
The antigenically and genetically closely related human respiratory 
syncytial virus (HRSV), which causes similar disease in humans, was first 
isolated from chimpanzees in 1956 and named chimpanzee coryza agent 
(Morris et al. 1956). In 1957 the same virus was isolated from human infants, 
and was later renamed HRSV, based on the formation of multinucleated giant 
cells or syncytia in inoculated human cell culture (Chanock et al. 1957; 
Chanock et al. 1962). 
Already in 1963, it was noted that certain calf sera inhibited in vitro 
cytopathic effects of HRSV (Taylor-Robinson & Doggett 1963), and in 1968 
Doggett et al. suggested this inhibition was mediated by bovine antibodies 
(Doggett et al. 1968). Subsequently, in 1970 a virus identified as BRSV was 
isolated from cattle with respiratory disease in Switzerland (Paccaud & 
Jacquier 1970) and Japan (Inaba et al. 1970), and later in the United States 
(Smith et al. 1975). 
Since then, both BRSV and HRSV have been shown to be highly prevalent, 
with high morbidity in calves and children, respectively (Meyer et al. 2008). 
Great efforts have been made to understand both viruses, and to develop 
preventive and therapeutic strategies. 
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1.2 Epidemiology 
BRSV is host specific to cattle (International Committee on Taxonomy of 
Viruses 2011), although occasional isolations and serological evidence indicate 
that sheep, goat and wild ruminant species may be infected (Evermann et al. 
1985; Lehmkuhl et al. 1980; Dunbar et al. 1985; Van der Poel et al. 1995; 
Gaffuri et al. 2006). While it appears that lambs are not very permissive to 
experimental BRSV infection alone, BRSV may play a role in predisposing or 
aggravating Mannheimia haemolytica infections in lambs (F. J. Trigo et al. 
1984; Sharma & Woldehiwet 1990a). Serological and in vitro studies with 
BRSV and HRSV have also suggested that swine may be infected with one or 
both of these viruses, or possibly a porcine pneumovirus, but such a virus has 
yet to be isolated (Fishaut et al. 1978; Allan et al. 1998). 
In cattle, BRSV is highly prevalent, with seroprevalence rates ranging from 
50-100%, with variation over time, geography and mean age of animal groups, 
and is considered endemic in large parts of the world (Van Vuuren 1990; Paton 
et al. 1998; Hägglund et al. 2006; Beaudeau et al. 2010; Saa et al. 2012). In a 
recent study involving 120 calves in 45 dairy and beef herds in eastern Poland, 
BRSV antigens were detected in nasal secretion from 64% of calves with signs 
of respiratory disease, and from 56% of calves with no respiratory signs 
(Urban-Chmiel et al. 2014). 
In regions with temperate climate, outbreaks of BRSV in cattle herds occur 
predominantly in the cold season, with clinical signs primarily in 
immunologically naïve animals (Stott et al. 1980). 
As BRSV do not appear to spread over great distances by aerosol, recurring 
outbreaks in herds are likely due to either reintroduction by direct or indirect 
transmission, or by reactivation of latent infection (Van der Poel et al. 1993). 
Although resumed virus shedding in persistent latent infection with BRSV in 
cattle has never been confirmed, low levels of viral protein expression has been 
demonstrated in B cells from pulmonary lymph nodes collected up to 71 days 
after infection (Valarcher et al. 2001). 
1.3 Impact of respiratory syncytial virus 
1.3.1 Impact of BRSV and its role in the bovine respiratory disease complex 
Bovine respiratory disease (BRD) is most often multifactorial, involving 
various viral, bacterial and environmental factors (Callan & Garry 2002). 
Therefore, the specific impact of BRSV on economics and animal welfare is 
impossible to calculate, although BRSV alone can cause severe lower 
respiratory disease in calves (Callan & Garry 2002), and is often the only 
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identified viral etiology during outbreaks of respiratory disease (Elvander 
1996; Uttenthal et al. 1996; Thea B. Klem et al. 2014). 
BRD constitutes a large proportion of the total morbidity of cattle, 
especially in young stock, causing extensive financial loss for producers in way 
of decreased production and increased veterinary expenses (Fulton 2009; Van 
der Poel et al. 1994). In the UK alone, an estimated 1.9 million calves were 
affected, and 157 000 calves died from BRD in 1995 (Reeve-Johnson 1999). 
This corresponds to economical losses to the cattle industry of £150 million per 
year in the UK, and by extrapolation, could amount to as much as €576 million 
per year in Europe as a whole (Reeve-Johnson 1999). According to another 
study which modeled BRD-associated costs, including associated increased 
morbidity, mortality, treatment and premature culling, and reduced production, 
the average added cost by BRD per heifer and year in a typical Dutch dairy 
herd, could be as high as €43 (van der Fels-Klerx et al. 2001). In the United 
States, 29% of calf losses in 2010 were caused by respiratory problems, 
excluding free-ranging calves lost to predators (USDA, National Agricultural 
Statistics Service 2011). 
1.3.2 Impact of HRSV 
HRSV is the foremost cause of lower respiratory disease worldwide (Nair et 
al. 2010), and the leading viral cause of pneumonia in children under the age of 
5 years (Rudan et al. 2011). In turn, pneumonia is the leading cause of 
mortality from infectious disease in this age group, with 900 000 deaths 
worldwide in 2013 (Liu et al. 2014). Infants are particularly vulnerable, and 
hospitalization rates peak in 1 month old infants, especially those born preterm 
(Hall et al. 2013). When the disease burden of respiratory viruses in 
hospitalized humans was scored using the Disability Adjusted Life Year 
(DALY) model, HRSV received the highest score in children (<5 years old; 
DALY score 67.7) and immunocompromised patients (DALY score 6.8), but it 
also received a high score in elderly patients (>65 years old; DALY score 
41.0), for whom only influenza constituted a greater disease burden (Gaunt et 
al. 2011). Therefore, developing effective control measures for HRSV is 
considered a priority by the WHO (Rudan et al. 2011). 
1.4 Virology 
1.4.1 Taxonomy 
BRSV is an enveloped negative sense single strand RNA (-ssRNA) virus in 
the Paramyxoviridae family, Pneumovirinae subfamily, and Pneumovirus 
genus (International Committee on Taxonomy of Viruses 2011). Analysis of a 
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limited number of RSV isolates from sheep and goats suggest that, whereas 
isolates from goats may be considered strains of BRSV, ovine RSV (ORSV) is 
more divergent (Evermann et al. 1985; M Trudel et al. 1989; Duncan & 
Potgieter 1993). HRSV is in the same taxonomic genus, but is more distantly 
related (International Committee on Taxonomy of Viruses 2011).  
1.4.2 Morphology 
The typical mature Paramyxoviridae virus particle is a spheroid virion, 
approximately 150 nm in diameter, but filamentous forms are often seen 
(International Committee on Taxonomy of Viruses 2011). The glycoprotein-
studded lipid envelope, together with the enclosed nucleocapsid and traces of 
non-structural viral proteins, form the BRSV virion. At the core of the spiral-
shaped nucleocapsid is the 15k nucleotide viral genome, with 10 genes, coding 
for 11 proteins (Table 1) (Valarcher & Taylor 2007). 
Table 1. BRSV proteins and their main characteristics 
Abbr. Protein name Sizea RSV 
identityb 
Major functionsc 
F Fusion protein 574 81 Membrane fusion 
G Attachment glycoprotein 257/263 30 Membrane attachment  
SH Small hydrophobic 
protein 
73 38 Promote attachment and fusion, 
suppression of apoptosis 
M Matrix protein  256 89 Virion packaging 
M2-1 Matrix protein 2-1 186 80 Promote read-through at gene 
junctions during transcription 
M2-2 Matrix protein 2-2 95 43 Mediate switch from transcription to 
replication 
NS1 Non-structural protein 1 136 69 Type I IFN inhibition and resistance 
NS2 Non- structural protein 2 124 84 Type I IFN inhibition and resistance 
N Nucleoprotein 391 93 Protect genome from degradation 
P Phosphoprotein 241 81 Unclear; interact with N, L and RNA 
L Large protein 2161 84 Form the polymerase complex with N 
and P 
a Number of amino acids (AA) in protein. 
b AA identity (%) between BRSV and HRSV, as determined in other studies (Lerch et al. 1991; Lerch et al. 
1990; Anderson et al. 1992; Samal & Zamora 1991; Zamora & Samal 1992; Pastey & Samal 1995; Samal et al. 
1991; Mallipeddi & Samal 1992; Yunus et al. 1998). 
c Major protein function/role in virulence and pathogenesis, as described further in the text. 
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1.4.3 Replication 
As the virion of a respiratory syncytial virus (RSV) buds off an infected 
host cell, the nucleocapsid is enclosed by an envelope of cellular membrane. 
The genome is stabilized and protected by the nucleoprotein (N) and the 
phosphoprotein (P); both essential for virion packaging (Teng & Collins 1998). 
Also associated with the nucleocapsid is the large protein (L) which, together 
with the N and P proteins, is proposed to form the polymerase complex (Tawar 
et al. 2009). 
Species-specific attachment and fusion of BRSV and HRSV with bovine 
and human cells respectively, is mediated by subunit F2 of the fusion protein 
(F), whereas contributions of the attachment glycoprotein (G) and the small 
hydrophobic (SH) protein to host cell attachment are less specific (Heminway 
et al. 1994; Schlender et al. 2003).  
Following fusion of the viral and cell membranes, the viral genome is 
released into the host cell cytoplasm, along with viral proteins carried in the 
virion. Using the viral genome as a template, the viral polymerase produces 
mRNA for protein synthesis, and positive sense RNA as templates for genome 
replication. The balance between protein synthesis and replication is modulated 
by transcription interruption at gene junctions, mediated by several viral 
proteins: the non-structural proteins 1 and 2 (NS1 and NS2), the two matrix-2 
proteins (M2-1 and M2-2), and the N and P proteins. The NS1 and NS2 
proteins promote protein synthesis, whereas the N and M2-2 proteins mediate a 
switch to viral replication, which is then sustained by the M2-1 protein. The 
role of the P protein in this process is not clear, but it is associated with the N, 
as well as the M2-1 protein (García et al. 1993). Protein synthesis from viral 
mRNA templates, as well as post-translational modifications of viral proteins, 
is achieved by utilizing the host cell machinery. 
During infection, the viral glycoproteins F, G and SH localize to the cellular 
membrane, where the F and SH proteins, and to a lesser degree the G protein, 
contribute to the formation of syncytia of infected cells (Heminway et al. 
1994). Oligomers of SH proteins may also increase membrane permeability by 
forming small molecule channels (Carter et al. 2010) and suppress apoptosis by 
inhibiting TNFα signaling (Fuentes et al. 2007; Taylor et al. 2014a). 
Finally, during exit from the cell, the initial bud is created by assemblies of 
F protein in the cell membrane, the tails of which associate with the matrix (M) 
protein (Liljeroos et al. 2013). The M protein, together with the M2-1 protein, 
extends the bud by forming tubules, and attracts the nucleocapsid. The G and 
SH proteins are assembled onto the bud, through association with the M and F 
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proteins. Tubules formed by the M protein elongate the bud, which eventually 
separates from the infected cell (Liljeroos et al. 2013). 
Thus, a new virion is created: with F, G and SH proteins on the outer 
surface of the lipid envelope; M, M2-1, and M2-2 proteins on the inner surface; 
enclosing the genome, N, P and L proteins in the nucleocapsid; along with 
small amounts of NS1 and NS2 proteins; and residual cellular proteins. 
Interactions between M proteins, on the inner surface of the initially elongated 
virions, tend to transform virions into spheroids (Liljeroos et al. 2013).  
1.4.4 Antigenic and genetic variability 
All BRSV isolates are of the same serotype, with less than 11% nucleotide 
divergence in the gene coding the G protein, which is the most variable gene 
(Larsen et al. 2000). Neutralization assays with monoclonal antibodies against 
the G protein indicate four different antigenic subgroups (A, AB, B, and 
untyped) (Schrijver et al. 1996). Shown in Figure 1, as modified from 
Valarcher et al. 2000 (Valarcher et al. 2000), gene sequencing and phylogenic 
analysis revealed six genetic subgroups (I-VI) based on variation in the gene 
coding for the G protein, and five subgroups, with less variation for the genes 
coding for the F and N proteins. 
The genetic distance between BRSV and HRSV is heterogeneous among 
the viral genes, as shown in Table 1 and Figure 1. For example, the amino acid 
identity between BRSV and HRSV genes coding for the G protein is only 30% 
(Lerch et al. 1990), whereas for the N protein it is 93% (Samal et al. 1991). 
However, as shown in Figure 1, the genetic variations within BRSV isolates 
are consistently much smaller for the genes coding for the F, G and N proteins, 
compared to the nucleotide distance to corresponding HRSV genes. 
 
Figure 1. Phylogenetic trees showing the relative nucleotide distance between isolates of HRSV 
(subtypes A and B), ORSV and the six suggested genetic subgroups of BRSV (I-VI), in genes 
coding for the attachment glycoprotein (G), the fusion protein (F) and the nucleoprotein (N), as 
reported by Valarcher et al. (Valarcher et al. 2000). The F gene was not sequenced for the ORSV 
isolate in that study. The dashed line indicates a nucleotide distance of 10%, in all trees. 
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1.5 Clinical signs and pathology 
Manifest primary BRSV infection is mostly seen in immunologically naïve 
animals; usually young calves where transfer of BRSV-specific maternally 
derived antibodies (MDA) have been inadequate, and older calves, with 
declining levels of specific MDA (Stott et al. 1980; Kimman et al. 1988). 
Commonly observed clinical signs are those of an upper airway infection, 
which may progress to bronchiolitis and interstitial pneumonia. Infection 
usually begins in the nasal mucosa or conjunctiva, with nasal and ocular 
discharge, and progresses to the lower airways, with coughing, abdominal 
dyspnea, tachypnea and adventitious lung sounds, which may include both 
wheezes and crackles (Bryson et al. 1983). In addition, severely affected 
animals may show non-specific signs, such as fever, depression, and reluctance 
to stand up or to eat. 
Typically, the severity of respiratory clinical signs observed corresponds 
with the severity and extent of lung pathology (Leruste et al. 2012). 
Macroscopically, lesions appear as patchy or coalescent areas of consolidated 
lung tissue, with a swollen and dark red appearance, predominantly in the 
cranioventral lobes (Bryson 1993). In severe cases, bullous emphysema may be 
observed, typically in the caudal lobes (Kimman, Straver, et al. 1989). 
Histologically, purulent bronchiolitis and alveolitis is typically seen in acute 
cases, with focal bronchiolar epithelial hyperplasia and necrosis, thickening of 
alveolar septa, and alveolar collapse (Bryson et al. 1978). Mucus, purulent 
debris and increased numbers of neutrophils are observed in bronchoalveolar 
lavage from BRSV-infected calves (Kimman et al. 1986). 
In addition to clinical signs attributed to BRSV replication and 
inflammation, co-infections (e.g. species of pasteurella and mycoplasma) are 
common, and the etiology of individual clinical signs and lesions cannot 
always be assigned to a specific agent (Bryson et al. 1978; Callan & Garry 
2002). 
In humans, severe HRSV disease in infancy has been linked to chronic 
HRSV sequelae such as asthma and wheezing later in life, and has been linked 
to permanent remodeling of the airways following severe HRSV infection in 
early infancy (Szabo et al. 2013; Sigurs et al. 2010). In contrast, similar long-
term complications following BRSV infection have not been reported in cattle, 
and moderate BRSV-induced lung pathology may be reversible (Castleman et 
al. 1985). 
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1.6 RSV experimental infection models 
1.6.1 BRSV infection models 
The study of BRSV and the evaluation of vaccines and therapies hinges on a 
reliable calf infection model. To be applicable to field conditions, and useful in 
e.g. vaccine evaluation studies, such a model needs to induce clinical signs in 
calves both with and without passive immunity. Ever since BRSV was first 
isolated four decades ago, many experimental infections have been published, 
often with virus shedding following infection, but limited specific respiratory 
clinical signs (Belknap et al. 1995; Taylor 2013). In 1972, Inaba and colleagues 
experimentally infected a seronegative calf by intranasal (i.n.) and intratracheal 
(i.t.) routes, with little resulting respiratory clinical signs despite virus shedding 
being detected in nasal secretions, and seroconversion occurring two weeks 
after infection (Inaba et al. 1972). A similar lack of clinical signs has been 
reported using i.n. and/or i.t. inoculation of both seronegative and seropositive 
calves (Jacobs & Edington 1975; Thomas et al. 1984; van der Poel et al. 1996). 
By employing repeated i.n. and i.t. inoculations of calves with or without 
passive immunity, some studies have reported more severe clinical signs 
(Bryson et al. 1983; Ciszewski et al. 1991; Belknap et al. 1991). Other studies 
however, still report only mild signs of BRSV infection, despite the repeated 
inoculations (Kimman, Westenbrink, Schreuder, et al. 1987; Otto et al. 1996). 
Additionally, some studies have reported severe clinical signs following 
experimental infection, but could not determine the importance of co-infections 
(Ciszewski et al. 1991), or preclude comparison with other studies by omitting 
key clinical parameters, such as changes in rectal temperature following 
challenge (Xue et al. 2010). 
Inhalation of aerosolized BRSV has been the most successful calf model in 
inducing clinical signs in seropositive calves: either alone (Hägglund et al. 
2004; Ellis et al. 2013), or in combination with i.t. inoculation (Larsen et al. 
1999; Tjørnehøj 2000; Tjørnehøj et al. 2003). Small aerosol droplets (<5µm 
diameter) have the potential to reach and simultaneously infect the entire lung 
(Hatch 1961), but whether such droplets can convey infectious BRSV has not 
been determined. 
To demonstrate clinical significance of the treatment effect of evaluated 
vaccines or antivirals, the infection model needs to induce clear clinical signs 
and marked pathology, besides virus shedding (Nakagawa & Cuthill 2007).  
Apart from the generally low level of clinical expression in published 
experimental BRSV infection studies in calves, the diversity of methodology in 
sampling and reporting clinical signs and pathology, makes comparison 
difficult and meta-analysis problematic. 
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Lambs, which are less costly than calves and highly available, have also 
been experimentally infected with BRSV but appear to be less permissive than 
calves. Although some infected lambs shed virus and seroconvert following 
challenge, they demonstrate very limited clinical signs and minimal airway 
pathology (Cutlip & Lehmkuhl 1979; Lehmkuhl & Cutlip 1979a; Lehmkuhl & 
Cutlip 1979b; F J Trigo et al. 1984; Sharma & Woldehiwet 1990b).  
1.6.2 HRSV infection models 
Although experimental HRSV infection has been studied in healthy adult 
volunteers (Bagga et al. 2013), studies in the populations at risk for severe 
lower respiratory infection (i.e. infants, elderly and immunosuppressed) are 
restricted to studying cases of natural infection. Thus, a multitude of animal 
models have been explored (Bem et al. 2011). Chimpanzees are highly 
permissive to HRSV infection, but the high cost and unavailability of 
seronegative individuals have resulted in only a limited number of studies in 
this species (Byrd & Prince 1997). In contrast, mice and cotton rats are widely 
used in HRSV challenge studies, and are highly available, as are 
immunological reagents for these species (Bem et al. 2011). Other species, like 
macaques and lambs, constitute a compromise, in being less permissive to 
HRSV infection than chimpanzees and less immunologically defined than 
mice, but also being readily available and more similar in size and physiology 
compared to human infants (Bem et al. 2011). 
Because of the similarities in epidemiology and clinical manifestation 
between HRSV and BRSV, experimental BRSV infection in calves is highly 
suited to study RSV pathogenesis in a natural host, and to evaluate vaccine 
candidates based on conserved proteins or identical attenuation approaches.  
1.7 Immune responses and immunity 
1.7.1 Passive immunity 
Due to high seroprevalence, BRSV-specific MDA, primarily of isotype IgG1, 
will be detectable in sera from most young calves in endemic regions, when 
fed sufficient quality and quantity colostrum in the first 24h post-partum 
(Uttenthal et al. 2000). These MDA have a serum half-life of approximately 36 
days and therefore most unexposed calves will be seronegative by 3 to 7 
months of age (Baker et al. 1986; Fulton et al. 2004). However, exposure 
during this period is highly likely in many herds, but might not be detected 
serologically due to suppression of humoral responses by specific MDA in 
calves (Kimman, Westenbrink, Schreuder, et al. 1987). 
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 Maternal leukocytes present in colostrum are also taken up in the intestine 
and transported to lymphoid tissue (Liebler-Tenorio et al. 2002), where they 
react, up to 1 week after ingestion of colostrum, when stimulated with specific 
pathogens (Donovan et al. 2007). While the duration of colostrum-derived 
pathogen-specific T cell responses appear to be short lived, these may 
stimulate the neonatal immune system and augment its development in a non-
specific manner (Reber et al. 2005). It might therefore be important to feed 
calves with fresh rather than exclusively frozen-thawed colostrum, in which 
cells are destroyed. 
Both protection from clinical disease, and the immunological memory 
induced, are related to serum titer of specific MDA at the time of primary 
infection, because specific MDAs tend to suppress the initial humoral response 
(Kimman et al. 1988; Belknap et al. 1991). Thus, calves with high titers of 
specific MDA may be partially protected from clinical disease, but vulnerable 
to reinfections, due to limited immune memory. Consequently, in colostrum-
fed calves disease is usually seen in calves older than 2 weeks old, with the 
most severe clinical signs observed in calves 1 to 3 months old (Kimman et al. 
1988). 
1.7.2 Innate immune responses 
In an early stage during BRSV infection, the innate immune system is activated 
by several pattern recognition receptors (PRRs) in host cells, which recognize 
conserved pathogen-associated molecular patterns (PAMPs) in BRSV proteins 
and RNA (Zeng et al. 2012). This triggers several signaling pathways, resulting 
in a cascade of pro-inflammatory and antiviral cytokines, including IFNγ, 
TNFα, IL-1, IL-6, IL-8 and type I IFN (IFNα/β) (Knott et al. 1998; Grell, 
Tjørnehøj, et al. 2005; Røntved et al. 2000; Gershwin 2012; Guzman & Taylor 
2014). IL-1, IL-6, and TNFα have local effects such as increasing diapedesis, 
and systemic effects, such as induction of fever and increased pain sensitivity. 
IL-8 is secreted by infected endothelial cells and activated macrophages, and 
induces neutrophil chemotaxis and phagocytosis (Baggiolini & Clark-Lewis 
1992). IFNγ is produced and secreted in response to primary BRSV infection, 
mainly by NK cells, dendritic cells, macrophages, and γδT cells, and acts by 
promoting specific and non-specific cellular immune responses to intracellular 
pathogens (Knott et al. 1998). Once the virus is replicating and viral proteins 
are expressed, the production of type I IFN is down-regulated by BRSV 
(Valarcher et al. 2003). 
In contrast to most other animals, cattle, and particularly young calves, have 
a high percentage of γδT cells (up to 60%-70% of T cells in calves) (Jutila et 
al. 2008). γδT cells are important in bovine neonatal innate immunity, and may 
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augment the acquired immune response to BRSV, following PRR-activation 
(TLR3 and TLR7) of γδT cells by BRSV (McGill et al. 2013). However, the 
numbers of γδT cells, and their systemic and local distribution, appear to be 
unaffected by primary BRSV infection in young calves (Mcinnes et al. 1999). 
γδT cells are also important immune regulators in cattle, partly by secreting the 
anti-inflammatory cytokine IL-10 (Guzman et al. 2014). 
1.7.3 Acquired immune responses 
Acquired immune responses to primary BRSV infection or vaccination are 
more or less suppressed by BRSV-specific serum MDA in calves, although 
immune memory may still be induced (Kimman, Westenbrink, Schreuder, et 
al. 1987). For many other pathogens, passively acquired serum antibodies 
suppress humoral, but not cellular, immune response (Niewiesk 2014); this 
also appears to be the case for BRSV (van der Sluijs et al. 2010). 
Protective acquired immunity to RSV depends on both humoral and cellular 
components. Whereas high titers of virus neutralizing serum IgG and mucosal 
IgA antibodies can potentially stop initiation of infection (Kimman, 
Westenbrink, Schreuder, et al. 1987; Lee et al. 2004), a cytotoxic T cell 
response is essential for effective clearance of established infection in the 
lower airways (Taylor et al. 1995; Rossey et al. 2014). Calves intranasally 
inoculated with BRSV developed specific cell mediated immune responses, 
which were detectable after 5 days, peaked after 21 days, and persisted for at 
least 42 days (Field & Smith 1984). Neutralizing antibodies, both systemic and 
local, are mainly directed at the F and G proteins (Walsh et al. 1987; 
Westenbrink et al. 1989; Taylor et al. 1997; Taylor et al. 2005), whereas 
cytotoxic T cell activity is induced by the F, N, M2-1 (Openshaw et al. 1990; 
Gaddum et al. 2003) and P proteins (G. Taylor, 2014, pers. comm.). 
In seronegative (colostrum-deprived) calves, primary infection induces 
serum antibodies of isotype IgM and IgA, IgG1 and IgG2, which are detectable 
by ELISA starting 8-10, 10-14 days, 13-17 days and 1-3 months after infection, 
respectively (Kimman, Westenbrink, Schreuder, et al. 1987). Similarly, 
neutralizing antibodies can be detected in serum 2 weeks after infection (Inaba 
et al. 1972). The duration of detectable serum antibodies, following primary 
infection of seronegative calves, varies from 2-4 weeks for IgM and IgA, and 
at least 4 months for IgG1 (Kimman, Westenbrink, Schreuder, et al. 1987; 
Uttenthal et al. 2000). The duration of IgG2 antibodies is unclear, but is likely 
longer than 4 months (Larsen 2000). 
In adult cattle, which may have a history of repeated BRSV exposure, IgG1 
antibodies can persist for at least 3 years (T. B. Klem et al. 2014).  
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In contrast to seronegative animals, primary infection of calves with 
moderate levels of specific MDA (colostrum-fed) induces no change in serum 
or local respiratory antibody titer, except for occasional weak IgM and IgA 
responses (Kimman, Westenbrink, Schreuder, et al. 1987). 
On the other hand, calves without serum antibodies, but with circulating 
BRSV-specific T cells (indicating immune memory from previous exposure), 
demonstrate more rapid and stronger humoral and cellular responses when 
challenged with BRSV, compared to unprimed calves (Sandbulte & Roth 
2002). 
Although no single immunological parameters has been shown to perfectly 
correlate with protection against BRSV following primary infection or 
vaccination, protection has been associated with humoral responses, in 
particular mucosal IgA secretion (Kimman, Westenbrink, Schreuder, et al. 
1987), as well as with cellular responses (Riffault et al. 2010).  
1.8 Pathogenesis 
1.8.1 Course of infection 
Based on experimental studies, natural BRSV infection is postulated to initiate 
as an infection of the upper airways, that can progress to pneumonia (Viuff et 
al. 1996). Upper respiratory and mild systemic clinical signs may occur as 
early as 2 days post-infection, whereas severe lower respiratory clinical signs 
usually culminate 7 days post-infection, and most clinical signs subside within 
10 to 15 days after onset (Inaba et al. 1972; Hägglund et al. 2004). During this 
progression, BRSV replicates initially in epithelial cells in the nasal cavity and 
over approximately 2 days extends into the trachea, bronchi, bronchioles and 
alveoli (Viuff et al. 1996). In other studies where calves were experimentally 
infected, BRSV was demonstrated in nasal secretion up to 12 days following 
infection (titers peaking at 4 to 6 days) (Elazhary et al. 1980), and in lungs 
between 3 and 13 days (Jacobs & Edington 1975; Castleman et al. 1985; Viuff 
et al. 2002; Valarcher et al. 1999). 
1.8.2 Viral mechanisms of pathogenicity 
The initial clinical signs and pathology observed during primary RSV infection 
are a consequence of viral replication. Ventilation is impeded in the lower 
airways when replication in epithelial cells causes impaired ciliary function 
and an excess of luminal cell debris and mucus, along with structural collapse 
of alveoli (Kimman, Straver, et al. 1989; Bryson et al. 1991; Viuff et al. 1996). 
Bronchoconstriction further impedes ventilation, and in primary BRSV 
infection might be partially mediated by the viral peptide virokinin (produced 
 25 
by post-translational proteolytic cleavage of the BRSV F protein) (Zimmer et 
al. 2003; Valarcher et al. 2006). This, along with the intrinsically poor 
collateral alveolar ventilation in the bovine lung, can facilitate development of 
emphysema due to air trapping in alveoli (Kimman, Straver, et al. 1989). In 
addition, tissue damage, poor ventilation, and the impaired mucociliary 
escalator, predisposes the host to secondary bacterial infections. 
1.8.3 Effects of the primary immune response and viral countermeasures 
Apart from the direct effects of viral replication, inflammatory responses in 
the host account for a considerable part of clinical signs and pathology, both 
during primary and secondary infection (Tregoning & Schwarze 2010). 
Whereas BRSV inoculation of tissue cultures causes obvious cytopathology, 
very little cytopathology is seen when monocultured bovine respiratory 
epithelial cells are infected (Valarcher & Taylor 2007). Such differences can be 
explained by the fact that certain viral mechanisms may influence the immune 
response in vivo. For example: 
Ø HRSV replication induces transcription of IL-8, an important mediator of 
mucosal inflammation, through cytoplasmic-nuclear translocation of NF-κB 
p65 subunit (RELA) in human alveolar epithelial cells (Garofalo et al. 
1996). 
Ø The non-structural RSV proteins NS1 and NS2 interfere with type I IFN 
(IFNα/β) production and signaling (Valarcher et al. 2003), and render 
infected cells resistant to the antiviral effects of IFNα/β (Schlender et al. 
2000; Bossert & Conzelmann 2002). Furthermore, wild-type HRSV 
demonstrate increased activation of IL-4 producing CD4+ T cells and 
decreased activation and proliferation of Th17 cells, compared to NS1-
gene-deleted HRSV, suggesting a Th2 type immune response, independent 
of IFNα/β signaling (Munir et al. 2011). 
Ø The SH protein of BRSV and HRSV inhibits tumor necrosis factor alpha 
(TNFα) signaling (Fuentes et al. 2007; Taylor et al. 2014a), and thereby 
suppresses apoptosis in infected cells. Apoptosis is an important means of 
defense against intracellular pathogens such as BRSV (Viuff et al. 2002). 
Ø A truncated and soluble form of the attachment protein G is secreted from 
HRSV infected cells, starting before the budding off of virions (Hendricks 
et al. 1988). This secreted form of the G protein is proposed to thwart 
immune responses, by tying up antibodies in the humoral response, and 
through its mimicry of the leukocyte chemoattractant CX3CL1 (fractalkine 
in humans) (Tripp et al. 2001) of the innate and adaptive cellular immune 
response. 
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Ø Purified HRSV F protein up-regulates the toll-like receptor 4 (TLR4), 
making airway epithelial cells more sensitive to present bacteria (Monick et 
al. 2003), but potentially also aiding the clearance of virus (Haynes et al. 
2001). On the other hand, low expression of TLR4 in cord blood from 
infants, has been associated with increased risk of developing severe HRSV 
disease (Inchley et al. 2013).   
 
The individual impact of these various mechanisms on RSV pathogenesis, 
and the extent to which extrapolation between BRSV and HRSV is valid, 
remains to be fully elucidated. Furthermore, there may be strain-dependent 
differences in virus/host interactions, that may effect the course and 
manifestation of infection and host responses (Valarcher & Taylor 2007). 
1.8.4 Immunopathogenesis 
Apparently immune-mediated aggravated disease caused by natural HRSV 
infection, after prior vaccination with a formalin inactivated (FI) HRSV, was 
first reported in 1969 by Kim et al., following a vaccine trial in infants and 
children (Kim et al. 1969). 
It was concluded that this exacerbated disease was caused by factors 
relating to the virus in the vaccine, as both unvaccinated children and children 
immunized with a parainfluenza type 1 vaccine, produced similarly by the 
same manufacturer, did not suffer exacerbated disease in the same HRSV 
outbreak (Chanock et al. 1970). 
A later study, which analyzed sera from that vaccine trial, showed that FI-
HRSV induced antibodies that bind to the F and G HRSV proteins, but failed 
to inhibit cell fusion and neutralize virus (Murphy et al. 1986; Murphy & 
Walsh 1988), possibly caused by distortion of viral epitopes by formalin 
inactivation. 
FI-RSV vaccine-induced immunopathology has been reproduced using FI-
HRSV in small animal models (Graham et al. 1993; Connors et al. 1994), 
macaques (De Swart et al. 2002), and using FI-BRSV in calves (Antonis et al. 
2003). 
Results from these animal models corroborated the induction of non-
neutralizing antibodies by FI-HRSV (Graham et al. 1993; Connors et al. 1994), 
and showed that FI-HRSV induced a Th2 biased immune response (Connors et 
al. 1992; Hussell et al. 1998), characterized by an influx of eosinophils in the 
lungs (Openshaw et al. 2001). It has also been suggested that these non-
neutralizing antibodies may form complexes with antigen in the lungs (Graham 
et al. 1993; Connors et al. 1994), which may in turn induce a detrimental 
inflammatory response (Kimman, Daha, et al. 1989; Nadal & Ogra 1990). 
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However, despite the use of several commercially available inactivated 
BRSV vaccines for the past several decades, there is only one report of 
aggravated disease in calves immunized with inactivated BRSV and 
subsequently naturally exposed to BRSV (Schreiber et al. 2000), suggesting 
that this phenomenon is a rarity in cattle. 
Thus, after 45 years of extensive studies in animal models to explain the FI-
HRSV vaccine-induced immunopathology observed in children in the 1960’s, 
uncertainties remain. 
1.9 Laboratory diagnostics 
1.9.1 Indirect diagnostics 
One commonly used diagnostic tool to attribute an outbreak of respiratory 
disease in a herd to BRSV infection is analysis of paired serum to detect 
seroconversions or significant increases of antibodies in an individual or a 
herd. Titers of antibodies may be determined either using a virus neutralization 
assay by quantifying the ability of sera to reduce infection in BRSV inoculated 
cells, or by ELISA where antigen-specific antibodies are quantified. Total 
BRSV antigen produced by inoculation of cells is commonly used, either to 
coat wells in an indirect ELISA, or as the antigen in a capture ELISA. 
However, specific antibodies can also be detected using ELISAs coated with 
individual proteins, such as G (Taylor et al. 1995) and N (Samal et al. 1993). 
For routine detection of seropositivity or seroconversion, BRSV-specific IgG 
antibodies are often measured (Hägglund et al. 2006). Assays selectively 
detecting IgA, IgM, IgG1 and IgG2 may be employed to establish timing of an 
outbreak (Kimman, Westenbrink, Straver, et al. 1987). 
1.9.2 Direct diagnostics 
Pre-existing high titers of antibodies, passively or actively acquired, may 
prevent or mask humoral responses. Thus direct detection of live virus, viral 
antigen, or viral RNA may be required to attribute an outbreak of respiratory 
disease to BRSV (Kimman et al. 1986). 
The presence of live BRSV in nasal secretion or bronchoalveolar lavage 
(BAL) may be ascertained by virus isolation, and virus quantified by titration 
and characterized by virus neutralization assay. This delicate process involves 
inoculation of the sample onto bovine kidney (Thomas et al. 1982), turbinate 
(Elvander 1996), or lung cells (Larsen et al. 1999), followed by either 
observation of virus specific cytopathic effect by light microscopy, staining of 
virus antigen by immunohistochemistry, or detection of virus RNA by 
molecular beacons (Santangelo et al. 2006). 
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Although demonstration of live virus is most convincing, inoculation of cell 
culture is not always practical, and there may be uncertainties about the 
viability of virus in samples collected in the field. In this context, 
demonstration of virus antigen(s) or RNA is an alternative. 
Immunofluorescent staining can be used to illustrate BRSV antigen in 
histological sections (Kimman et al. 1986; Viuff et al. 1996), whereas antigen 
ELISAs can be used in the field to detect BRSV antigens in body fluids 
(Valarcher et al. 1999; Tjørnehøj et al. 2003). Recently, a rapid HRSV antigen 
detection test, containing monoclonal antibodies against HRSV proteins F and 
N, was shown to yield results with a high level of agreement with reverse 
transcription quantitative PCR results (RT-qPCR), when nasal secretions from 
calves were analyzed (Urban-Chmiel et al. 2013; Urban-Chmiel et al. 2014). 
Whereas isolation can prove etiology, and antigen immunofluorescent 
staining can indicate the extent of viral antigen present, conventional or RT-
qPCR is more sensitive (Larsen et al. 1999; Hakhverdyan et al. 2005; Boxus et 
al. 2005), and can detect viral RNA in BAL fluid up 13 days following 
experimental infection in calves, compared to 5 days for virus isolation and 
immunofluorescent staining (Valarcher et al. 1999). 
Recently, a method termed droplet-real-time PCR reportedly shortened the 
assay time to 10 min (Uehara et al. 2014), when detecting BRSV using 
previously published RT-qPCR primers and probe (Willoughby et al. 2008) 
1.10 Vaccines 
Since BRSV is highly prevalent worldwide, eradication on a herd or regional 
level would leave naïve animals susceptible to reintroduction, with occurrence 
of potentially severe clinical disease in cattle of all ages. 
On the other hand, effective vaccination of unexposed animals and herds 
can protect individual animals from clinical disease, and in addition protect 
herds by stopping viral replication, thereby reducing the risk of transmission 
into and within that herd.  
Calves need to be vaccinated at an early age, to protect them when they are 
co-mingled. However, the development of an effective BRSV vaccine in young 
calves faces four basic obstacles: (i) immunological immaturity in young 
calves tend to attenuate vaccine responses (Chase et al. 2008); (ii) immune 
responses are often suppressed by BRSV-specific maternally derived 
antibodies (MDA) in sera of young calves; (iii) vaccination needs to induce a 
balanced and long lasting immune response, exceeding that induced by natural 
infection in young calves with specific MDA; and (iv) vaccination must be 
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safe, and avoid vaccine-induced immunopathology, as reported for some RSV 
vaccines. 
In addition, to facilitate serological analysis to monitor virus transmission, 
as well as vaccine efficacy and safety, vaccination should induce an immune 
response that can be differentiated from that induced by infection. 
 
1.10.1 Commercially available BRSV vaccines 
Live BRSV vaccines, attenuated by serial cell culture passages, have been 
commercially available for 40 and 30 years, in Europe and the USA 
respectively (Meyer et al. 2008; Fulton 2009). Mostly due to safety concerns, 
these modified live vaccines (MLV) were all licensed for parenteral use, with 
limited ability to overcome the inhibitory effect of specific MDA in young 
calves (van der Poel et al. 1999). 
As with many other pathogens, mucosal immunity to RSV is more 
effectively induced through mucosal immunization, compared to parenteral 
immunization, especially in the presence of specific MDA (Belyakov & Ahlers 
2009; Kimman, Westenbrink, Schreuder, et al. 1987; Kimman, Westenbrink, et 
al. 1989). 
Consequently, after demonstrating increased efficacy in calves with passive 
immunity using the mucosal route, compared to the parenteral route of 
vaccination, one of these MLVs was licensed for intranasal use (Vangeel et al. 
2007). Nonetheless, both clinical and virological protection following 
challenge were only partial, and of short duration (Ellis et al. 2013). Moreover, 
when conventional colostrum-fed calves, with varying levels of serum specific 
MDA, were vaccinated intranasally with that vaccine, they shed virus in nasal 
secretions for up to 20 days after vaccination (Timsit et al. 2009). 
 Thus, safety concerns with MLVs remain: specifically the risks of 
reversion to virulence, of exacerbating disease when administered during a 
natural BRSV outbreak (Kimman, Sol, et al. 1989), and of vaccine 
contamination, e.g. with bovine viral diarrhea virus (BVDV) (Palomares et al. 
2013). Furthermore, although MLVs induce immune responses similar to those 
following natural infection in calves, these might not be sufficient (Gershwin 
2012). 
Inactivated vaccines circumvent the risk of genetic reversion, and by 
utilizing different adjuvants the induced immune response can be directed and 
extended. The immunomodulating effects of adjuvants are achieved through 
various mechanisms, such as increased non-specific inflammation at the site of 
immunization (e.g. aluminum hydroxide), slowed release and prolonged 
exposure to the antigen (e.g. emulsions), enhanced uptake of antigen by 
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antigen presenting cells (APCs) (e.g. immunostimulating complexes, 
ISCOMs), and by activating additional arms of the immune system (e.g. TLR 
agonists, cytokines and antigen specific antibodies) (Aucouturier et al. 2001; 
Getahun & Heyman 2006; Tritto et al. 2009; Heegaard et al. 2011; Gregory et 
al. 2013; Garg et al. 2014). Commercially available inactivated BRSV vaccines 
use either aluminum hydroxide, Quil A, or a combination of the two (van der 
Sluijs et al. 2010; Ellis et al. 2007; Vangeel et al. 2007). 
1.10.2 HRSV vaccine development 
In contrast to the many commercially available BRSV vaccines, there is 
currently no available vaccine against HRSV (Rudraraju et al. 2013). Historical 
HRSV vaccine candidates have failed either due to safety concerns (Kim et al. 
1969), or have proven ineffective in children with specific MDA (Belshe et al. 
1982). However, several candidate vaccines are in clinical stages of evaluation, 
including recombinant live HRSV vaccines (i.e. ClinicalTrials.gov id 
NCT01459198 and NCT01968083) and recombinant vector vaccines 
expressing HRSV protein (ClinicalTrials.gov id NCT01805921). 
Based on the successful use of passive immunoprophylaxis in at-risk 
infants, using humanized monoclonal anti-HRSV antibodies (Wright & 
Piedimonte 2011), the focus in HRSV vaccine research has recently shifted 
somewhat from infant immunization, to maternal immunization during 
pregnancy (Kaaijk et al. 2013). Maternal immunization has proven effective 
for many other pathogens, and may prove effective for HRSV, especially for 
preterm neonates (Chu & Englund 2014). 
1.10.3 Differentiation of infected from vaccinated animals 
Vaccination programs using any of the commercially available BRSV 
vaccines require repeated boosts to fully protect calves during the first year of 
life, and have an additional drawback: infection in a vaccinated animal or herd 
cannot be detected serologically, because animals vaccinated with a complete 
virus vaccine cannot be distinguished serologically from infected animals. On 
the other hand, exclusion from the vaccine formulation of at least one viral 
protein, which is immunogenic yet non-essential for protection, will enable 
continued serological differentiation of infected from vaccinated animals 
(DIVA) (van Oirschot et al. 1986), as illustrated in Figure 2. Ideally, a 
companion DIVA assay enables identification of animals or herds that were 
infected and were contagious, after prior vaccination. This allows continued 
serosurveillance in regions where vaccination programs are instituted, and 
furthermore provides the means to monitor changes in vaccine efficacy and 
safety. 
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Figure 2. Exclusion of at least one viral protein from the vaccine formulation allows serological 
differentiation between infected and vaccinated animals (DIVA), in contrast to full virus vaccines. 
1.10.4 New generation RSV vaccine strategies 
In summary, vaccination of young colostrum-fed calves with currently 
available commercial BRSV vaccines does not offer full clinical and 
virological protection, or requires repeated boosts during the first year of life. 
Furthermore, their use precludes seromonitoring for circulating virus, or to 
monitor vaccine efficacy in the field. The key to effective immunity against 
BRSV in young calves seems to be induction of a balanced Th1/Th2 immune 
response, with neutralizing antibodies, as well as CD4+ and CD8+ T cell 
activity (Meyer et al. 2008; Gershwin 2012). Also, in contrast to those acting 
on a single arm of the immune system, multimodal immune responses are more 
likely to induce long lasting memory (Bevan 2011). 
New generation RSV vaccines use novel adjuvants and rationally selected 
antigens to overcome the shortcomings of currently available commercial 
vaccines, with the aim to induce balanced and long lasting immune responses, 
and are DIVA-compatible by omitting at least one viral protein. Viral proteins 
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can be selected by specific purification of infected cell lysate, with varying 
levels of purity. However, scientific and technological advances in genetic 
engineering allow definitive exclusion of specific viral proteins, as well as the 
introduction of attenuating point mutations in selected genes. 
The NS1, NS2, SH, G, F and M2-1 genes have been targeted for attenuation 
in live vaccines (Valarcher et al. 2003; Malkin et al. 2013). Point mutations 
may impart sufficient attenuation (Wright et al. 2000), but carry the risk of 
reversion to virulence (Lin et al. 2006). This risk can be drastically reduced by 
recombinant deletion of entire viral genes.  
Deletion of the SH gene is one of the most promising attenuation strategies 
for live recombinant BRSV (∆SHrBRSV) (Taylor et al. 2014a) and HRSV 
(MEDI-559) (Malkin et al. 2013). ∆SHrBRSV induced protective immunity in 
calves with low levels of specific MDA, after prior intranasal immunization 
(Taylor et al. 2014a), but requires additional investigations in calves with 
levels of specific MDA mimicking field condition, to further evaluate safety, 
immunogenicity and protective efficacy. 
Genetic engineering has also produced DNA vaccines (Taylor et al. 2005) 
and virus vectored vaccines (Taylor et al. 1997; Bian et al. 2014; Kim et al. 
2014; ClinicalTrials.gov id NCT01805921), often including the immunogenic 
proteins F, G, N and M2-1 proteins. Recombinant RSV proteins can be 
produced in cell culture, such as human embryonic kidney cells (McLellan et 
al. 2010), insect cells (Smith et al. 2012) and E. coli (Tran et al. 2007), or in 
plants (Lau & Korban 2010). Several subunit vaccines involving the HRSV F 
protein have demonstrated immunogenicity in cotton rats (Raghunandan et al. 
2014), mice (Glenn et al. 2013) and macaques (McLellan et al. 2013), with 
induction of predominantly neutralizing antibodies.  
Proteins conserved between BRSV and HRSV (e.g. F, N, P and M2-1) may 
provide cross-protection. The HRSV N protein, presented as N nanorings (Tran 
et al. 2007), have been shown to induce strong N-specific memory T cell 
responses and partial protection against experimental BRSV infection in 
seronegative calves (Riffault et al. 2010). Furthermore, when the ectodomain 
of the matrix protein 2 from influenza H1N1 was recombinantly attached to 
HRSV N nanorings, immunized mice demonstrated protection from both 
HRSV and influenza challenge (Hervé et al. 2014), suggesting that attaching 
epitopes from BRSV to N nanorings may similarly induce protective 
responses. 
The protein content in RSV vaccines can also be modulated by different 
methods of specific or non-specific purification of infected cell lysate, and by 
antigen/adjuvant formulation. Classic BRSV-ISCOMs, i.e. purified BRSV-
infected cell lysate formulated with immunostimulating complexes, were 
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shown to contain proteins F and N (M. Trudel et al. 1989; Trudel et al. 1992) 
and induced both neutralizing antibodies and cytotoxic T cell responses in mice 
(M. Trudel et al. 1989; Trudel et al. 1992). Moreover, BRSV-ISCOMs induced 
neutralizing serum and mucosal antibody responses in calves with BRSV-
specific MDA and a high level of clinical and virological protection, which 
exceeded that induced by an inactivated commercial vaccine (Hägglund et al. 
2004). 
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2 Aims of the thesis 
 
The overall objective of this thesis work was to develop and evaluate new 
generation vaccines against BRSV, specifically:  
Ø To evaluate, in calves with specific maternal immunity, the safety, 
immunogenicity and protective efficacy of a BRSV vaccine based on whole 
inactivated virus antigens in classic ISCOMs, and to characterize the 
antigen content in this formulation. 
Ø To formulate two subunit DIVA-compatible vaccines against BRSV. 
Ø To establish and characterize a BRSV-challenge model in calves with 
passive immunity, by combining protocols and methods from previous 
studies. 
Ø To evaluate the safety, specific immune responses and protection induced 
by two subunit formulations and one recombinant live BRSV vaccine in 
calves with maternal antibodies. 
 
 36 
 
 37 
3 Materials and methods 
The intention of the text in this section is to clarify methods used in each 
experiment involved in this thesis, and to indicate similarities and differences 
between experiments. In some sub-sections, for further technical details the 
reader is directed to publications that are included in this thesis. In other sub-
sections, details are given where they were omitted in publications. 
3.1 Cells and viruses 
3.1.1 Cells 
Calf kidney (CK) cells, bovine turbinate (BT) cells and Vero cells at low 
passages were cultured at 37°C in Dulbecco’s modified Eagle medium 
(DMEM, Lonza, Belgium), with 20 ml 1 M Hepes buffer (Lonza, Belgium), 10 
ml 200 mM l-glutamine (Lonza, Belgium), 10 ml 0.9% NaCl solution, 60 mg 
benzyl penicillin sodium (Recip AB, Sweden) and 100 mg streptomycin sulfate 
salt (Sigma Aldrich, Sweden), added per liter DMEM. Fetal calf serum (FCS, 
PAA Laboratories GmbH, Austria) was added to the supplemented DMEM, at 
concentration of 5%, 10% or 20% (DMEM-FCS 5%, 10% and 20%, 
respectively). 
3.1.2 Viruses 
Two isolates of BRSV were used for experimental challenges described herein 
and are referred to as: BRSV-Dk (no. 9402022, Denmark (Viuff et al. 1996), 
and BRSV-Snk (Snook strain, (Thomas et al. 1982)). BRSV-Dk was isolated 
and passaged five times in fetal bovine lung cells (Viuff et al. 1996), followed 
by two (study I) or three (study III) passages in BT cells. After initial isolation 
in CK cells (Thomas et al. 1982), BRSV-Snk was passaged three consecutive 
times in gnotobiotic calves, where each inoculum was prepared from BAL and 
administered by respiratory route, as described in detail elsewhere (Valarcher 
 38 
et al. 2003). Both inocula were verified to be free of contaminating viruses, 
including BVDV, and bacteria, including mycoplasma, as described in paper I 
and III. Inocula and other virus sample titers were determined by plaque assay 
on CK cells, with the unit pfu/ml, as previously described (Stott et al. 1980), or 
by endpoint dilution assay on BT cells, with the unit TCID50/ml, as previously 
described (Hägglund et al. 2004). 
3.2 Candidate vaccine production and formulation 
3.2.1 Production of BRSV antigen and BRSV-ISCOM vaccine 
BRSV antigen and BRSV-ISCOMs were produced before the start of this 
thesis project. Briefly, BRSV antigens used for vaccine formulation in study 1 
and 2, as well as for RT-qPCR positive control and ELISA antigen, were 
produced using BRSV-Dk, as described for the BRSV-Dk inoculum, except 
propagation and titration which were done in Vero cells. These BRSV antigens 
were purified by ultracentrifugation over sucrose, solubilized using octyl 
glucoside and separated through a sucrose gradient, as described in detail in 
paper II. ISCOMs with incorporated BRSV proteins (BRSV-ISCOMs) were 
produced by incubating a fraction of the solubilized antigen with cholesterol, 
phosphatidylcholine and Quillaja saponin, followed by purification by dialysis, 
ultracentrifugation and sterile filtering, as described in detail in paper I and II. 
BRSV protein used as control antigen in paper I and II, was processed as 
described for BRSV-ISCOMs, without adding lipids and Quillaja saponin. As 
adjuvant control for the BRSV-ISCOMs in paper I, a commercial ISCOM 
matrix adjuvant, containing cholesterol, phosphatidylcholine and Quillaja 
saponin from the same batch, was used (AbISCO-300, Novavax, previously 
Isconova, Uppsala, Sweden). In addition, ISCOMs formulated with uninfected 
Vero cell lysate (Vero-ISCOMs), otherwise identical to BRSV-ISCOM 
formulation, was used as control when characterizing BRSV-ISCOMs in paper 
II. Presence of infectious BRSV in the BRSV-ISCOM vaccine was ruled out 
by negative virus isolation. 
3.2.2 Characterization of BRSV-ISCOMs 
Aliquots of the undiluted BRSV-ISCOM vaccine formulation were analyzed to 
characterize the protein content. Aliquots of undiluted BRSV proteins and 
Vero-ISCOMs were used as controls. The protein concentrations in BRSV-
ISCOMs, BRSV proteins and Vero-ISCOMs were 1.46 mg/ml, 1.43 mg/ml and 
0.73 mg/ml, respectively; as determined by the Bradford assay (Bradford 1976) 
and amino acid analysis (Amino Acid Analysis Center, Uppsala University, 
Sweden) (Moore et al. 1958). 
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The morphology and size of BRSV-ISCOMs were investigated by negative-
stain transmission electron microscopy (TEM; FEI Tecnai 10 G2 microscope; 
2kx2k Morada CCD camera; iTEM control software, Olympus Soft Imaging 
Solutions GmbH; Vironova AB, Sweden). 
BRSV proteins were identified by size and antigenicity, using SDS-PAGE, 
Western blot (Towbin et al. 1979), and dot-blot, with protein specific 
monoclonal antibodies, and hyperimmune sera from calves experimentally 
infected with BRSV (BRSV-Dk or strain 391-2), as described in detail in paper 
II. In addition, visually detectable bands on SDS-PAGE gels from three 
separate batches of BRSV-ISCOMs were analyzed by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF; Uppsala University, 
Sweden; and INRA, France) (Tran et al. 2009), and entire lanes were analyzed 
by liquid chromatography tandem mass spectrometry (LC-MS/MS; PAPPSO 
platform, INRA, France) (Arfi et al. 2013). The size and intensity of bands in 
digital images of SDS-PAGE gels was used to estimate the relative quantity 
between individual proteins, using ImageJ analysis software) (Schneider et al. 
2012). Data from LC-MS/MS were used to find matches for proteins in the 
following protein databases: Macaca mulatta (UniprotKB, 06/24/2013), BRSV 
(strain A519086, UniprotKB 06/21/2013, and BRSV-Dk), and an in-house 
contaminant database (INRA, France).  
3.2.3 Subunit vaccines containing HRSV P, M2-1 and N-nanorings with BRSV 
epitopes  
Construction, expression and purification of recombinant RSV proteins 
Recombinant HRSV protein with epitopes from BRSV included in the subunit 
vaccine formulations in paper IV, were constructed, produced and purified by a 
project partner in this thesis work, and this process is described in detail in 
paper IV. In brief, E. coli were transformed with plasmids to express full-
length HRSV M2-1 or -P proteins, or HRSV N protein nanorings decorated 
with epitopes from BRSV (Table 2). N nanorings, with 10 or 11 protomers, 
were constructed and formed by co-expression of full-length HRSV N protein 
and amino acid residues 161-241 of the HRSV P protein, as described 
elsewhere (Tran et al. 2007; Tawar et al. 2009). The BRSV epitope-decorated 
N-nanorings (eN) used in the subunit vaccines were constructed by 
recombinantly attaching selected residues to the N or C terminus of the N 
protein, and expressed and purified as described for N nanorings (Table 2). The 
attached residues represent key epitopes on BRSV proteins F (AA 255-278 and 
422-438) and G (AA 174-187), and one combinatorial peptide mimicking 
antigenic site II on the BRSV F protein (mimotope) (Chargelegue et al. 1998) 
(Table 2). All HRSV recombinant protein were constructed using the HRSV 
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Long strain sequence (GenBank accession no. AY911262), and BRSV epitopes 
using BRSV-Dk sequences (Larsen et al. 1998), and constructs verified by 
sequencing. Expressed protein concentration was measured by absorption at 
280 nm (M2-1 and P) or the Bradford method (eN). 
Table 2. Recombinant HRSV proteins and BRSV epitopes used in subunit vaccine formulation. 
Recombinant HRSV proteins P and M2-1 were included as full-length proteins. N nanorings are 
formed by co-expression of the HRSV N protein (Long strain) and a fragment of HRSV P protein 
(Long strain, AA residues 161-241; Tran et al. 2007). N nanorings with recombinant epitopes 
attached to each of the 10 or 11 protomers (eN) were constructed by grafting indicated residues 
to the N or C terminus of the N protein. 
Protein product Description Sequence origin 
P Full length P protein HRSVa 
M2-1 Full length M2-1 protein HRSVa 
eN-F255-278 Residues 255-278 of F at N terminus of N in eN 
(AA: SELLSLINDMPITNDQKKLMSSNV) 
BRSVb 
eN-F422-438 F residues 422-438 at C terminus of N in eN  
(AA: CTASNKNRGIIKTFSNG) 
BRSVb 
eN-Fmimo Residues mimicking epitope on Fc at C terminus  
of N in eN (AA: HWSISKPQ) 
Combinatorial 
peptide 
eN-G174-187 G residues 174-187 at N terminus of N in eN  
(AA: STCEGNLACLSLCQ) 
BRSVb 
a HRSV Long strain (GenBank accession no. AY911262). 
b BRSV strain 9402022 (Larsen et al. 1998). 
c Antigenic site II (AA residues 422-438) on protein F, as described by Chargelegue et al. (1998). 
Formulation of subunit vaccines 
In paper IV, subunit vaccines SUMont and SUAbis were formulated, both with 
25 µg/dose each of recombinant proteins HRSV M2-1, HRSV P, eN-F255-278, 
eN-F422-438, eN-Fmimo and eN-G174-187, diluted in PBS (Table 2). For each dose 
of SUMont, 0.6 ml of protein suspension (150 µg of total protein) was mixed 
and emulsified with 1.4 ml of Montanide ISA71VG (SEPPIC, France), 
according to the manufacturer’s instructions. For each dose of SUAbis, 144 µl 
(390 µg) of AbISCO-300 (Novavax, Sweden) and 150 µg of total protein were 
diluted in PBS to a final volume of 2 ml. A placebo vaccine, formulated as 
SUAbis without protein, was used as control in paper IV. 
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3.2.4 Recombinant SH-gene-deleted live BRSV vaccine 
The recombinant BRSV with deleted SH gene (∆SHrBRSV) used as live 
vaccine in paper IV was constructed by a project partner in this thesis, using 
full-length cDNA from BRSV strain A51908 (Mohanty et al. 1975), variant 
Atue51908 (GenBank accession no. AF092942), as previously described 
(Karger et al. 2001). ∆SHrBRSV was propagated in Vero cells and verified to 
be free of BVDV, as previously described (Valarcher et al. 2003). The use of 
∆SHrBRSV, a genetically modified microorganism, for experimental intranasal 
vaccination of calves in paper IV, was approved by the Swedish Work 
Environment Authority (registration number 202100-1868 v8a1). 
3.3 Calves 
Calves of Swedish Holstein or Swedish red and white breed were obtained 
from two conventional dairy herds (herd 1 and herd 2) for experiments 
reported in papers I, II, III and IV (Table 3).  
Both herd 1 and 2 were certified to be free of BVDV and bovine leucosis. 
Seromonitoring in both herds (as described in detail in each paper) for 
detection of BRSV infections indicated that included calves were BRSV naïve. 
However, as discussed below for paper III, this appeared not to be valid for one 
animal.  
Group allocation for each experiment aimed to generate homogenous 
groups, with regard to age and titer of BRSV-specific MDA. The assigned 
treatment for each group, within each experiment, was randomized. 
Groups of calves in paper I and II were housed in separate pens, whereas 
groups of calves in paper III and IV were housed in separate rooms with 
anteroom and negative pressure ventilation, and separate protective clothing 
for staff. All calves had free access to water and hay, and rations of calf pellets 
twice daily. In addition, calves were fed milk replacer twice daily, except in 
paper III.  
All animal experiments described herein were carried out in accordance 
with the EU Directive 86/609, and were approved by the Ethical Committee at 
the district court of Uppsala, Sweden (Ref. no. C68/10 and C330/11). 
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Table 3. Experimental groups and calf ages. Calves were obtained for experimental vaccination 
and BRSV challenge (reported in paper I, II and IV), or for experimental BRSV challenge alone 
(reported in paper III), or as sentinels for transmission of live vaccine (paper IV), or as 
uninfected controls (paper III), as described in material and methods. Calf identities used to refer 
to calves in this thesis are the same as those used in the paper indicated. 
Paper Group n Calf identities 
Age at immunization 
(weeks) 
Age at challenge 
(weeks) 
I & II BRSV-ISCOM 5 a-e 6 (3-8) 11 (8-13) 
BRSV protein 5 f-j 6 (5-8) 11 (10-13) 
 Adjuvant 5 k-o 6 (5-7) 11 (10-12) 
 PBS 5 p-t 6 (4-8) 11 (9-13) 
III BRSV-Snk 3 A1-A3  10 (8-13) 
 BRSV-Dk 3 B1-B3  10 (8-11) 
 Uninfected 3 D1-D3  13 (8-15)a 
IV ∆SHrBRSV 5 a1-a5 7 (4-9) 12 (9-14) 
 SUMont 5 b1-b5 6 (3-10) 11 (8-15) 
 SUAbis 5 c1-c5 7 (2-9) 12 (7-14) 
 Controls 5 d1-d5b 6 (2-11) 11 (7-16) 
 Sentinels 3 s1-s3 6 (4-7)  
a Refers to age at commencement of experiments, equivalent to the day of challenge in infected calves. 
b Referred to as calves C1-C5 in paper III. 
3.4 Experimental vaccination 
3.4.1 Paper I 
In paper I, four groups of five calves each (Table 3) were immunized twice 
with an interval of two weeks, subcutaneously with: (i) BRSV-ISCOMs 
containing 188 µg protein in 2 ml PBS; (ii) 188 µg BRSV protein in 2 ml PBS; 
(iii) 390 µg AbISCO-300 in 2 ml PBS; or (iv) 2 ml PBS. 
3.4.2 Paper IV 
In paper IV, four groups of five calves each (Table 3) were immunized: group 
(a) i.n. with ∆SHrBRSV (5x106 pfu in 6 ml of DMEM); group (b) 
intramuscularly (i.m.) with 2 ml of SUMont; group (c) subcutaneously (s.c.) 
with 2 ml of SUAbis; and group (d) s.c. with 2 ml of placebo. Group (a) was 
immunized once, whereas groups (b), (c) and (d) were immunized twice, with 
an interval of three weeks. 
To avoid spread of the live vaccine to the other groups, group (a) was 
housed in a separate room until three weeks after vaccination, in a separate unit 
of the animal facility that had separate ventilation. In addition to the measures 
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described to isolate each room in a unit, each unit had separate staff, and 
showers were required to exit each unit. 
To detect possible transmission of the live vaccine (∆SHrBRSV), three 
seronegative sentinel calves were co-housed with group (a), starting the day 
after vaccination, for six consecutive days. During this time, and for two 
additional weeks after being isolated from group (a), sentinels were clinically, 
immunologically and virologically monitored for indications of transmission of 
vaccine virus. Replication of the live vaccine (∆SHrBRSV) in the upper 
airways was also monitored in group (a) following vaccination by collecting 
and analyzing nasal secretion for the presence of BRSV RNA by RT-qPCR. 
Three weeks after first vaccination, one calf (c5) in group (c) was 
euthanized due to a traumatic leg injury. 
3.4.3 Post-vaccination monitoring of calves (papers I and IV) 
Calves were monitored clinically following vaccination, including daily 
recording of rectal temperature, and any local or systemic adverse effect of 
immunization. If any, local swelling at the site of injection was classified as 
mild (<5x5 cm), moderate (<10x10 cm), marked (<15x15 cm) or severe 
(>15x15 cm) (paper IV). 
3.5 Experimental infection of calves by aerosol inhalation 
On post-infection day (PID) 0 all calves, except sentinels and uninfected 
controls, were challenged by inhalation of aerosolized virulent BRSV, in three 
different experiments (papers I, III and IV). In paper I calves were challenged 
with BRSV-Dk (105.0 TCID50 in 3 ml DMEM), in paper III with either BRSV-
Dk (104.4 pfu in 5 ml DMEM; calves B1-3) or BRSV-Snk (104.0 pfu in 5 ml 
DMEM; calves A1-3), and in paper IV with BRSV-Snk (104.0 pfu in 4 ml 
DMEM). In both vaccine evaluation experiments (papers I and IV), calves 
were challenged five weeks after first vaccination (two weeks after boost, 
where applicable). Inocula were aerosolized by a compressor/nebulizer system 
(Super Dandy Inhaler, PARI, Germany), and the resulting aerosol inhaled via a 
tightly fitting face mask (Swevet Piab AB, Sweden) (Figure 3), which was well 
tolerated by calves. 
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Figure 3. Face mask and nebulizer used for aerosol BRSV challenge in calves.  
3.6 Clinical monitoring after challenge 
Following challenge on PID 0, daily clinical examinations of all calves were 
carried out, and clinical signs were recorded. 
Clinical examinations included: general state and appetite; recording rectal 
temperature and respiratory rate; presence of ocular or nasal discharge, or of 
spontaneous coughing, breathing pattern and reaction to cough provocation; 
auscultation of lungs for increased or adventitious respiratory sounds; as well 
as direct or indirect signs of diarrhea. 
Clinical scores were calculated from recorded clinical signs, using two 
different scoring systems (detailed in paper I for that experiment, and paper III 
for the other experiments). Accumulated clinical scores (ACS) were calculated 
using the Trapezoid method. Note that, even though ACS represents the area 
under curves of clinical scores from infection to termination of each 
experiment, the experiment reported in paper I was one day shorter in duration, 
and used a different clinical scoring system, compared to experiments reported 
in paper III and IV. 
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3.7 Passive measurement of lung function 
The effect of BRSV infection on the lung function of calves was determined by 
the forced oscillation technique (EquineOsc Calf measurement head, EEMS, 
Harts, UK), on PID -1 (paper I) or 0 (paper III) and again on PID 6. Airway 
resistance and reactance (kPa/L/s) were measured at 3, 5, 7 and 10 Hz, as 
described elsewhere (Reinhold et al. 1996), using the same tightly fitting face 
mask used for aerosol inhalation (Figure 3). For daily calibrations, a 2.26 m 
long tube with a 21 mm internal diameter was used. On each occasion, every 
calf was tested in two series, and series were repeated if coughing or breath-
holding was observed. The series with optimal coherence was selected 
(coherence>0.9). 
3.8 Live sampling before and after challenge 
Heparinized and whole blood samples, for extraction of peripheral blood 
mononuclear cells (PBMCs) and serum respectively, and nasal secretion for 
detection of BRSV by RT-qPCR and virus isolation, were collected before and 
after challenge, as indicated in Figure 4. Additionally, in paper IV, nasal 
secretions were collected following vaccination; from animals vaccinated with 
∆SHrBRSV on post-vaccination day (PVD) 2, 4-7, 11 and 14, and from three 
seronegative calves acting as sentinels for transmission of live vaccine on PVD 
0-8, 11 and 14. Serum was also collected from sentinel calves on PVD 20. In 
paper III, BAL was performed in sedated calves (calves A1-3 and B1-3), on 
PID -1, as described in detail in paper III. 
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Figure 4. Samples collected from calves challenged with BRSV in three separate experiments. Additional samples of serum and nasal secretion were collected 
following vaccination in paper IV; from calves immunized with live vaccine, and from calves acting as sentinels 
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3.9 Post-mortem examination and sampling 
All infected calves were euthanized on PID 6 (paper I) or PID 7 (papers III and 
IV) by an intravenous overdose of ketamine (5 mg/kg) and pentobarbital 
sodium (15 mg/kg), followed by exsanguination. 
During post-mortem examination lungs were photographed, palpated and 
lesions recorded on lung charts. The extent of lung lesions (%) was calculated 
by digital image analysis of lung charts (Adobe Illustrator CS5, version 15.1 
for Macintosh). 
In all infected calves, as well as uninfected control calves in paper III 
(Table 3), BAL was performed on excised lungs; 500 ml of PBS was poured 
into the trachea, with lobes in the right lung clamped off, and then BAL fluid 
was collected by gravity into a sterile glass bottle and stored on ice until a 
centrifugation step (200 x g, 10 min) to separate BAL cells and BAL 
supernatant. BAL cell pellets were resuspended in DMEM-FCS 20% for virus 
isolation or RLT buffer (Qiagen, Sweden) for RNA extraction, and stored at -
70°C. BAL supernatant was also stored at -70°C until subsequent antibody and 
cytokine analysis. 
Lung tissue samples were collected post-mortem for histological 
examination; one tissue sample from the accessory lobe, and three (paper I) or 
one (paper III and IV) tissue sample(s) from each of the remaining three lobes 
in the right lung, as well as a sample from the trachea, were fixed in 10% 
buffered formalin, and paraffin sections prepared. In each lung lobe, grossly 
abnormal areas were sampled, where available. In paper I, an additional 
pneumonic lung tissue sample was homogenized in DMEM-FCS 20% for virus 
isolation. 
3.10 Detection of BRSV 
3.10.1 Quantification of BRSV RNA 
Total RNA was extracted from nasal secretions and BAL cells, and BRSV 
RNA quantified by BRSV F gene RT-qPCR, as described in papers I, II, IV 
and elsewhere (Hakhverdyan et al. 2005). Equivalent titers of RNA (TCID50 
equivalent) were derived by correlation with a standard curve, constructed by 
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the inclusion in each run of dilutions of a virus sample with known titer (105.0 
TCID50 in paper I and 105.8 TCID50 in papers III and IV). 
Accumulated virus shed (AVS), was calculated using the Trapezoid 
method, based on BRSV RNA detected in nasal secretion collected daily, from 
infection to euthanization (PID 6 for paper I; PID 7 for papers III and IV). 
3.10.2 Detection of BRSV antigen 
The process of immunohistochemical staining of BRSV antigen in sections of 
lung tissue is described in detail in paper III. In brief, microwave heat-induced 
epitope retrieval was used to unmask antigens. This was followed by 
deactivation of endogenous peroxidases using 3% H202, blocking unspecific 
binding using 2% bovine serum albumin (BSA), incubation with RSV-specific 
monoclonal antibodies, binding to primary antibodies by secondary antibodies 
attached to a dextran polymer backbone with peroxidase enzymes, staining 
with diaminobenzidine, and counterstaining with haematoxylin. 
3.10.3 Isolation of live BRSV 
Isolation of live BRSV was attempted by inoculation of samples suspended in 
DMEM onto 95% confluent BT cells in 25 cm2 culture flasks. After incubation 
for 1h at 37°C, inocula were poured off and replaced with DMEM and 
incubated at 37°C for six (paper I) or seven (papers III and IV) days. During 
this incubation, cultures were examined daily using light microscopy and any 
cytopathic effects recorded. Samples inducing cytopathic effects were 
considered positive for live BRSV. Consecutive passage of negative samples, 
as indicated in respective results, was done by transfer of cell lysate into new 
25 cm2 culture flasks with fresh BT cells, and monitored as described for the 
first passage. 
3.11 Measuring immunological parameters 
3.11.1 Quantification of antibodies 
BRSV neutralizing antibodies were measured in heat-inactivated samples by a 
plaque reduction assay using fetal calf kidney cells, as described previously 
(Kennedy et al. 1988). 
BRSV-specific IgG1 antibodies were measured by a commercial indirect 
ELISA (BRSV-Ab ELISA, Boehringer Ingelheim Svanova, Sweden), 
according to instructions. Corresponding kits from the same manufacturer were 
also used to detect IgG antibodies against BVDV, bovine coronavirus and 
bovine parainfluenza virus type 3 in paper I. 
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BRSV-specific IgG2 antibodies were measured by exchanging the 
conjugated antibody in the BRSV-specific IgG1 ELISA, for mouse-anti-
bovine-IgG2 followed by rat-anti-mouse-IgG1 conjugated with horseradish 
peroxidase (HRP). 
BRSV-specific IgA was measured by capture ELISA (as modified from 
Uttenthal et al. 2000), as described in paper I. Briefly, plates were coated with 
mouse-anti-bovine-IgA antibodies and blocked with BSA, followed by 
sequential incubation with: sample, BRSV or uninfected cell lysate, mouse-
anti-BRSV N protein antibody, rat-anti-mouse-IgG1:HRP, 
tetramethylbenzidine (TMB) substrate; and H202. 
IgG antibodies specific for BRSV G, F, M, P and SH were analyzed by 
ELISA, as described previously for the G protein (Taylor et al. 1995). Antigen 
and control antigen for these ELISAs were produced in chick embryo 
fibroblasts infected with recombinant fowlpox or wild-type fowlpox viruses, as 
described previously (Gaddum et al. 2003). 
IgG antibodies against HRSV F, N, P and M2-1 were measured by ELISA 
as described previously for N (Riffault et al. 2010). Antigens were produced 
and purified as previously described for N (N, P and M2-1) (Roux et al. 2008) 
and F (McLellan et al. 2011). IgA antibodies against HRSV N were measured 
by coating microtiter plates with N protein (as for IgG), followed by blocking 
with BSA, and sequential incubation with: sample, mouse anti-bovine IgA; rat 
anti-mouse IgG2a:HRP; TMB substrate; and H202. 
Antibodies competing with monoclonal antibody 19 (mAb 19), known to 
neutralize both HRSV and BRSV (Arbiza et al. 1992), were analyzed by 
competitive ELISA, wherein plates were coated with BRSV protein (control 
antigen in paper I and II) and blocked with 2% horse milk, followed by 
sequential incubation with serially diluted samples, mAb 19, rat-anti-mouse- 
IgG2a: HRP, TMB substrate and H2O2. 
For all antibody ELISAs, optical density (OD) was measured at 450 nm. 
After the corrected optical density (COD) was calculated by subtraction of 
relevant background OD, levels of antibodies were presented either as (i) titer, 
derived from serial dilution of each sample, followed by calculation of end-
point titer by linear regression using a negative sample as cut-off reference; or 
(ii) as percent COD (%COD) of a positive reference sample at dilution 1:25. 
3.11.2 BRSV-specific lymphocyte proliferation assay 
PBMCs were isolated from heparinized blood, diluted 1:1 in PBS, by 
centrifugation at RT (1100 x g, 30 min) over Ficoll Paque Plus medium (GE 
Healthcare, Sweden). After this PBMCs were recovered in the interface layer 
and washed three times by centrifugation in PBS (500 x g 10 min, then twice 
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200 x g, 10 min), then resuspended in RPMI medium (Lonza, Belgium, 
supplemented as described for DMEM, and betamercaptoethanol at 5 x10-5 M) 
with 5% FCS. After mechanical disruption of tracheobronchial lymph nodes 
(LN), mononuclear cells were isolated as described for PBMCs, but 
centrifuged for 8 minutes at 800 x g over Ficoll Paque Plus medium. Isolated 
PBMCs and LN mononuclear cells were seeded into wells on 96-well cell 
culture plates, and restimulated in triplicate using BRSV antigen (heat-
inactivated BRSV-Dk infected BT cell lysate) and control antigen (heat-
inactivated uninfected BT cell lysate), and then incubated at 37°C with 5% 
CO2. To detect cell viability in each stimulation condition, and relative cell 
proliferation, Alamar Blue® (Invitrogen, Sweden) was added to each well after 
six (paper I) or seven (paper IV) days of incubation. After an additional six 
(PBMCs paper I), eight (PBMCs paper IV) or twenty-four (LN cells) hours of 
incubation, optical densities were measured in each well at 570 nm (OD570nm) 
and 595 nm (OD595nm) (Multiskan EX 355, Thermo Fisher Scientific, USA). 
Mean COD was calculated by subtracting the adjusted OD (OD570nm-OD595nm) 
of control antigen-stimulated wells, from the adjusted OD of BRSV antigen-
stimulated wells, and calculating a triplicate mean. Supernatants of stimulated 
wells were recovered after centrifugation (200 x g, 5 min, 20°C), and stored at 
-80°C for cytokine analysis. 
3.11.3 Flow cytometric analysis of BRSV-specific IFNγ-producing lymphocytes 
For flow cytometric analysis, tracheobronchial LN mononuclear cells were 
isolated and restimulated as described for the proliferation assay, except they 
were restimulated in duplicate wells, and incubated for 18h, with brefeldin A 
(10 µg/ ml; Sigma, Sweden) for the last 15h. Glycoproteins CD4 and CD8 
were stained in stimulated cells (MCA1653F:FITC (CD4), MCA837A647: 
AlexaFlour 647 (CD8), AbD Serotec, Sweden). Dead cells, with compromised 
membranes, were stained by a dye reacting with free amines in the cell interior 
(LIVE/DEAD Fixable Near-IR Dead Cell Stain, Life Technologies, Sweden). 
After fixation (4% paraformaldehyde, 10 min) and membrane permeabilization 
(FACS permeabilization solution 2, BD Biosciences, Sweden), cells were 
stained for intracellular IFNγ (MCA1783PE: RPE (IFNγ), AbD Serotec, 
Sweden). The fluorescence of stained cells was analyzed by flow cytometry 
(FACSVerse, FACSuite software, BD Biosciences, Sweden). Gates for live, 
non-aggregating cells were based on fluorescence at 783/56 nm and light-
scattering properties. Gates for CD8+, CD4+ and IFNγ producing cells were set 
based on Fluorescence Minus One controls. 
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3.11.4 Detection of cytokines  
Detection of cytokines by immunosorbent assays 
In paper IV, supernatant from PBMCs restimulated with BRSV (described for 
the proliferation assay) was analyzed using commercially available kits 
detecting IFNγ and IL-4 (Bovine IFNγ ELISA, MCA5638KZZ and Bovine IL-
4 ELISA, MCA5892KZZ, Bio-Rad, Sweden). Both assays were performed 
according to instructions from the manufacturer for respective kits, and 
concentrations of cytokines calculated based on an included standard sample, 
and expressed as ng/ml. 
After 20X concentration of BAL supernatant (BAL20X), by filtered 
centrifugation (UFC900324, Amicon Ultra-15, 3kDa, Merck Millipore, 
Sweden; swinging bucket rotor, 4000 x g, 25-30 min), IFNγ and IL-4 were 
analyzed in BAL20X as described for PBMC supernatant. Similarly, by 
following instructions of commercial ELISA kits and deriving sample 
concentrations from a relevant standard sample, IL-6 (ESS0029 Bovine IL-6 
ELISA, Pierce, USA), IL-8 (ABIN414016 Bovine IL-8 ELISA, Antibodies 
Online, Germany) and TNFα (VS0285B-002 Bovine TNFα ELISA, Divbio 
Science Europe, The Netherlands) were analyzed in BAL20X. 
Detection of cytokines by RT-qPCR 
In paper I, PBMCs were isolated and restimulated with BRSV, as described for 
the proliferation assay, with the following modifications for analysis by RT-
qPCR: after 24h of incubation, cells were pelleted by centrifugation (200 x g, 5 
min, 20°C) and total RNA extracted (RNeasy Mini Kit, Quiagen, Sweden). 
Samples were analyzed using bovine-specific IFNγ-, IL-4- and 28S-RT-qPCR 
(iScript One-Step RT-PCR kit for probes and an IQ5 realtime PCR machine, 
Bio-Rad, Sweden), as previously described (Rosbottom et al. 2007). IFNγ and 
IL-4 were analyzed in triplicates, and 28S in duplicates. The house-keeping 
gene 28S was used to standardize detected cytokine levels, and results are 
expressed as: copies of cytokine mRNA / 1000 copies of 28S rRNA. 
3.12 Histological assessment and scoring of severity of 
inflammation in lesioned lung sections 
Slides with sections of trachea and lung tissue with gross lesions, were stained 
with: (i) hematoxylin and eosin (HE) for morphological description, or (ii) 
Luna's eosinophil stain (paper I) or carbol chromotrope stain (paper III and IV) 
to indicate eosinophils. A pathologist described and scored the severity of 
histopathology and inflammation in each slide as either normal (0), mild (1), 
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moderate (2) or severe (3). A mean score of histopathological severity was 
calculated for each calf, based on all lung tissue slides for that animal. In paper 
III, additional corresponding slides from each animal were stained by BRSV-
specific immunohistochemistry (described in detail in the section 3.10.2 
Detection of BRSV antigen). 
3.13 Data analysis 
3.13.1 Ranking of animals 
Within each calf experiment presented in this thesis, calves were ranked with 
regard to three measurable outcomes of experimental BRSV infection: 
accumulated clinical score or ACS (clinical rank), extent of lung lesions (lung 
lesion rank), and accumulated virus shed in nasal secretion or AVS (viral-shed 
rank). In each experiment, rank 1 was assigned to the calf with the lowest ACS, 
least lung lesions and lowest AVS, in each of the three ranks respectively. 
More affected calves were assigned consecutively higher ranks. Statistics were 
calculated based on the individual sum of these three ranks. For each group of 
calves, three rank sums were calculated, as well as a total rank sum. 
3.13.2 Statistical analysis 
Results are presented as group mean ± one standard deviation (SD), where not 
otherwise stated. Standard deviations of percentages are presented as 
percentage point (pp). Data were analyzed using one-way ANOVA followed 
by Dunnett’s test (paper I and II; Minitab 16.1.1, Minitab Inc.) or Student’s t-
test (papers III and IV; JMP 10 for Mac, SAS Institute Inc.), or Kruskal–Wallis 
analysis followed by Wilcoxon test (papers III and IV; JMP 10 for Mac, SAS 
Institute Inc.). Significance was assumed when p≤0.05. 
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4 Results 
4.1 Evaluation of immunogenicity and protective efficacy of 
BRSV-ISCOMs in calves with BRSV-specific maternal 
antibodies (Paper I) 
To confirm and extend previously reported immunogenicity and high level of 
protective efficacy of BRSV antigen in classic ISCOMs (BRSV-ISCOMs) in 
older calves, young calves with specific MDA were immunized with BRSV-
ISCOMs, and challenged with BRSV. Furthermore, to elucidate the influence 
of the adjuvant in BRSV-ISCOMs, additional calves were immunized with 
BRSV protein alone, or adjuvant alone. Finally, calves injected with PBS acted 
as double negative controls. 
4.1.1 Immunogenicity of BRSV-ISCOMs 
Immune responses were investigated by analyzing isotypes of antibodies in 
serum, nasal secretion and BAL supernatant; and by ex-vivo BRSV 
restimulation of isolated PBMCs, and subsequent analysis of cell proliferation 
and estimation of IFNγ and IL-4 gene expression through mRNA detection. 
Vaccinated calves had varying titers of colostrum-derived BRSV-specific 
serum IgG antibodies before first vaccination (mean±SD log10 titer 1.9±0.3; 
Table 2 in paper I), which were declining until first vaccination. Corresponding 
titers in calves immunized with adjuvant or PBS continued to decrease 
throughout the experiment. Adventitious BRSV infection was furthermore 
ruled out by repeated seromonitoring of seronegative sentinel animals. 
In contrast to all control calves, BRSV-ISCOM vaccinated calves 
demonstrated increasing levels of BRSV-specific serum IgG after a single 
immunization (4/5 calves), with an augmented increase after boost (5/5 calves).  
Serum concentrations of IgG1 and IgG2 antibodies in BRSV-ISCOM-
immunized calves were significantly elevated on PID -2 and PID 5, compared 
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to all controls (p≤0.0001). Similarly, levels of mucosal IgA in nasal secretion 
and BAL were significantly elevated on PID 5 and 6, respectively, compared to 
all controls (p≤0.005 and p≤0.01). 
In addition, after challenge (on PID 4), 4/5 BRSV-ISCOM-immunized 
calves demonstrated BRSV-specific proliferative responses in isolated 
circulating lymphocytes, compared to none of the calves in all other groups. 
Furthermore, in this group significantly increased quantities of IL-4 and IFNγ 
mRNA were detected in restimulated cells, compared to calves immunized 
with adjuvant or PBS for IL-4 (p≤0.05) and for IFNγ (p≤0.05) when compared 
to cells from all other calves. The mean ratio of IL-4 to IFNγ mRNA was 1:46 
in cells from BRSV-ISCOM-immunized calves, suggesting a Th1 type immune 
response. 
No adverse reactions to immunization were observed following the first 
vaccination, or following the second vaccination with BRSV protein or PBS. 
However, mild to moderate local swellings and elevated rectal temperature 
(40.0-40.3°C) was observed 12h (persisting up to 48h) after second 
immunization with either BRSV-ISCOMs or adjuvant alone. 
4.1.2 Protection induced by BRSV-ISCOMs 
Following challenge in paper I, calves immunized with BRSV-ISCOMs 
showed no or very minor clinical signs, indicating a high level of clinical 
protection, whereas mild to severe respiratory disease was observed in all other 
calves. Calves immunized with BRSV proteins alone showed predominantly 
mild to moderate clinical signs of respiratory disease, indicating they were 
afforded at least partial clinical protection. On the other hand, calves 
immunized with adjuvant alone or PBS developed moderate to severe clinical 
signs of disease, including purulent nasal discharge, coughing, wheezing lung 
sounds, increased respiratory rate (peak 76 breaths/min), elevated rectal 
temperature (peak 41°C), and subjectively, various degrees of depression. 
When the accumulated clinical score (ACS) was calculated, BRSV-ISCOM-
immunized calves received the lowest ACS (mean±SD 1.3±1.9), followed by 
BRSV-protein (mean±SD 2.9±1.0), PBS (mean±SD 6.7±6.7), and adjuvant 
immunized calves (mean±SD 9.0±5.9 ACS). The difference in ACS between 
BRSV-ISCOM and adjuvant immunized calves was significant (p≤0.05). 
The accumulated clinical signs observed in each group corresponded to the 
extent of consolidated lung lesions on post-mortem examination at PID 6. The 
least amount of lung lesions were observed in calves immunized with BRSV-
ISCOMs (mean±SD 3.8±2.9%), followed by calves immunized with BRSV 
protein (mean±SD 7.5±6.0%), adjuvant (mean±SD 15.7±14.5%), and PBS 
(mean±SD 16.1±8.7). Similarly, when a pathologist scored ten areas per calf, 
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the extent of gross lung pathology corresponded to the severity of 
histopathology: BRSV-ISCOM being lowest (mean rank 5.6), followed by 
BRSV protein (mean rank 9.2), adjuvant (mean rank 11.8), and highest being 
PBS (mean rank 15.4). 
The accumulated virus shed (AVS), representing BRSV RNA detected in 
nasal secretion from PID 0 to PID 6, was also significantly reduced in BRSV-
ISCOM-immunized calves (mean±SD 0.3±0.5 log10 TCID50 eq.), compared to 
all control calves (p≤0.0001), which shed more than seven logs more virus 
following challenge (mean±SD for BRSV protein alone, adjuvant alone and 
PBS, 7.5±2.5, 7.4±2.4 and 7.9±2.8 log10 TCID50 eq., respectively). 
Thus, BRSV-ISCOM-immunized calves were both clinically and 
virologically protected from virulent BRSV infection. Taken together, BRSV-
ISCOM vaccination afforded immunized calves significant protection, 
compared to all other groups of calves, when total rank sums were calculated 
(p≤0.05; Figure 5). In contrast, calves immunized with BRSV protein alone 
were not protected. 
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Figure 5. Ranking of clinical signs, extent of lung lesions, and virus shed in calves following 
experimental BRSV infection after prior immunization. Four groups of five colostrum-fed calves 
were immunized twice at an interval of three weeks with BRSV-ISCOMs, BRSV protein, 
adjuvant alone, or PBS; and challenged with BRSV by aerosol inhalation two weeks later. 
Following challenge, clinical signs and virus shed in nasal secretion was recorded for six days, 
when lung lesions were recorded at post-mortem. Low ranks were assigned to those with low 
accumulated clinical signs (low clinical rank), sparse lung lesions (low lung lesion rank), and low 
accumulated virus shed (low viral-shed rank). The figure shows each rank sum per groups, and 
each stack represent the group total rank sum. The significantly lower total rank sum of the 
BRSV-ISCOM-immunized calves, compared to all other groups (p≤0.05), indicates they were 
protected from BRSV infection. 
 
4.2 Characterization of BRSV-ISCOMs (Paper II) 
The promising results in paper I prompted further investigation of the BRSV-
ISCOM vaccine, to enable further improvement and standardization of the 
BRSV-ISCOM formulation, or to develop a recombinant subunit vaccine. 
Therefore, the morphology and antigenicity of BRSV-ISCOMs was 
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investigated in paper II, by electron microscopy and both qualitative and semi-
quantitative characterization of the protein content, using gel electrophoresis, 
Western blot, dot blot and mass spectrometry (MALDI-TOF and LC-MS/MS). 
Electron microscopy imaging of the BRSV-ISCOM vaccine revealed 
pleomorphic cage-like ISCOM particles with diameters of 40-90 nm 
(mean±SD 56.4±11.1 nm, n=1644), as well as smaller and less defined 
particles (10-20 nm diameter). 
BRSV proteins F and N were clearly identified in BRSV-ISCOMs by size 
separation in Coomassie blue stained SDS-PAGE gels. Using digital image 
analysis of these gels, and by measuring the total protein concentration in the 
BRSV-ISCOM vaccine used for immunizations, each dose of vaccine (188 µg 
total protein) was estimated to contain 77 µg of F and 17 µg of N protein. 
Analysis by MALDI-TOF verified that these bands, cut out from SDS-
PAGE gels, contained the F and N proteins, respectively. In addition to these 
viral proteins, Vero cell derived integrins, CD9 and histone H4, were identified 
by MALDI-TOF, in separate cut out bands from the same SDS-PAGE gels. 
Visually identical results were obtained with three different batches of BRSV-
ISCOMs and selected bands were confirmed by MALDI-TOF. 
Dot blot and Western blot analysis, using a panel of monoclonal antibodies 
and hyperimmune calf sera, confirmed the presence of the F and N proteins, 
but also demonstrated the presence of G, M, M2-1, and P proteins in both the 
BRSV-ISCOM and the BRSV protein vaccine formulations. 
Using the highly sensitive method LC-MS/MS to identify peptide 
sequences in BRSV-ISCOMs, the F, N, M, M2-1, and P proteins were 
demonstrated, but also the SH protein and Vero cell derived proteins (e.g. 
integrins). However, the G protein was not detected when lanes from SDS-
PAGE gels were analyzed by LC-MS/MS, which might be due to limited 
migration of the glycosylated G protein. 
To investigate the immunogenicity of identified proteins, sera from calves 
in paper I were further analyzed in paper II. 
Analysis of sera from BRSV-ISCOM-immunized calves, collected 2 weeks 
after second vaccination, but before challenge, demonstrated significantly 
elevated titers of antibodies directed against proteins F, N and G (N p≤0.001; F 
and G p≤0.05), compared to calves immunized with ISCOM matrices alone 
(AbISCO-300; Figure 6). Furthermore, low titers of antibodies against proteins 
M and P, and high titers of antibodies against the SH protein were detected in 
BRSV-ISCOM-immunized calves, although this was not statistically 
significant compared to calves immunized with adjuvant alone (Figure 6). 
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In addition, mAb 19 competing antibody titers were measured to 
approximate the neutralizing capacity of sera from BRSV-ISCOM-immunized 
calves, and these were significantly higher (p≤0.001) than those of all controls 
(mean (range) log10 titer 2.4 (1.7-2.6), 1.5 (0-2.2), 0.3 (0-1.0) and 1.2 (0-1.5) 
for calves immunized with BRSV-ISCOM, BRSV proteins, AbISCO-300 or 
PBS, respectively). 
 
Figure 6. BRSV protein specific antibodies in sera from calves immunized with BRSV-ISCOMs. 
Five calves were immunized with BRSV-ISCOMs, as described in section 3.4.1. In addition, five 
calves were immunized identically, but with ISCOM matrices alone (adjuvant). The figure shows 
mean titer of antibodies directed against viral proteins F, N, G, P, M and SH, in sera collected 
from BRSV-ISCOM-immunized calves before challenge, two weeks after second vaccination. 
Vertical lines indicate standard deviation. Arrows indicate corresponding mean titer of calves 
immunized with adjuvant alone, and asterisks indicate statistical difference compared to these 
calves (p≤0.05 (*); p≤0.001 (***)). 
4.3 Refinement and characterization of a BRSV infection model 
in calves (Paper III and IV)  
In paper III, to enable the joint vaccine evaluation described in paper IV, which 
involved three project partners, and to facilitate comparability with follow-up 
studies, protocols and methods previously used by project partners were 
consolidated into a common BRSV calf infection model. This process involved 
the evaluation of two previously used inocula, BRSV-Snk passaged in 
gnotobiotic calves and BRSV-Dk passaged in cell culture, to determine which 
induced the most field-like BRSV disease. Two groups of three calves with 
low levels of BRSV-specific serum IgG1 antibodies (mean±SD 4.1±4.8 %COD 
on PID 0) were challenged by aerosol inhalation of either inoculum. 
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Figure 7. Ranking of clinical, pathological and virological outcomes in calves experimentally 
infected by aerosol inhalation of either BRSV-Dk or BRSV-Snk. Following challenge, nasal 
secretions were collected daily, and calves were clinically monitored for seven days, when calves 
were euthanized. Lung lesions were recorded post-mortem. Based on this data, ranks were 
assigned as described in Figure 5. Clinical rank is indicated on the x-axis, lung lesion rank on the 
y-axis, and viral-shed rank by the number inside and the size of each bubble. Calf identities are 
indicated next to each bubble.  
 
4.3.1 Characterization of clinical, pathological and virological expression of two 
inocula (Paper III) 
All infected calves were markedly affected by experimental infection, 
although BRSV-Snk infected calves were consistently more affected, as 
illustrated by clinical, pathological and virological ranks (Figure 7). Individual 
rank sums were significantly higher in BRSV-Snk infected calves (p≤0.01), 
and their total group rank sum was twice as high, compared to BRSV-Dk 
infected calves (42 and 21, respectively). This was despite the fact that one 
BRSV-Snk infected calf (A1) rapidly seroconverted after challenge (BRSV-
specific IgG1 in sera diluted 1:25: 5 %COD on PID 0 and 91 %COD on PID 
7), suggesting this calf had been previously exposed to BRSV, despite 
seromonitoring in the herd of origin from 17 days after the birth of this calf. 
The difference in rank sums reflects that, following challenge, BRSV-Snk 
infected calves were significantly more clinically affected (ACS: 46.2±4.5, 
compared to 20.0±13.5; p≤0.05), had more extensive lung lesions 
(38.5±26.3%, compared to 12.8±14.6%), and shed more virus in nasal 
secretion (AVS: 12.6±8.1 TCID50 eq., compared to 8.0±4.0 TCID50 eq.), 
compared to calves infected with BRSV-Dk. 
The difference in clinical score, in turn, reflects the marked difference 
between the two groups of calves, in clinical disease observed following 
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challenge. On PID 7, all BRSV-Snk infected calves were depressed and had 
reduced or absent appetite, whereas only one BRSV-Dk infected calf (B2) had 
an affected general state, and none demonstrated reduced appetite. 
A full account of clinical signs of respiratory disease observed in these 
calves is given in paper III. In brief, clinical signs observed in BRSV-Snk 
infected calves following challenge were characterized by coughing, 
tachypnea, enhanced and wheezing lung sounds, abdominal dyspnea, pyrexia, 
with general depression and reduced appetite. 
Lung lesions observed in BRSV-Snk infected calves on PID 7 were 
predominantly located in the cranioventral lobes. Macroscopically, lesions 
were dark red and consolidated, with excessive mucus and pus in bronchi. 
Histologically, lesions were characterized by moderate to severe 
bronchointerstitial pneumonia, purulent bronchitis and bronchiolitis with 
prominent peribronchiolar lymphoid-cell hyperplasia, and fibrinosuppurative 
alveolitis. 
BRSV-Dk infected calves demonstrated similar lung lesions, but less 
extensive and less severe, both macroscopically and histologically (mild to 
moderate bronchointerstitial pneumonia). 
Both groups of calves had similar histological lesions in the trachea on PID 
7: with degeneration, desquamation and focal hyperplasia of trachea 
epithelium, and intraepithelial infiltrate of polymorphonuclear leukocytes, 
predominantly neutrophils. Interestingly, whereas immunohistochemically 
stained BRSV antigen was abundant in the tracheae, but almost undetectable in 
the lungs of BRSV-Dk infected calves, the opposite was true for 2/3 BRSV-
Snk infected calves (A2 and A3). No BRSV antigen was detected by 
immunohistochemistry in the trachea or lungs of the BRSV-Snk infected calf 
A1, which seroconverted after challenge. 
This calf (A1) also shed substantially less virus in nasal secretion collected 
from PID 0 to PID 7, and in BAL on PID 7 (AVS/BAL: 3.6/1.7 log10 TCID50 
eq.), compared to the other two BRSV-Snk infected calves (AVS/BAL: (A2) 
19.3/3.3 log10 TCID50 eq.; (A3) 14.9/3.5 log10 TCID50 eq.). Virus shed varied 
in BRSV-Dk infected calves (AVS/BAL: (B1) 3.5/2.8 log10 TCID50 eq.; (B2) 
9.4/2.3 log10 TCID50 eq.; (B3) 11.1/2.7 log10 TCID50 eq.), but was less than that 
of calves A2 and A3. 
However, live BRSV was isolated in the first passage, in both nasal 
secretions from PID 6 and BAL fluid from PID 7 from all infected calves. 
When BAL cells collected before and after challenge (PID -1 and PID 7) 
were analyzed, a significant increase in total number of cells following 
challenge was evident in calves infected with BRSV-Snk, both compared to 
before challenge ((PID -1) 1.0±0.2 x106 cells/ml; (PID 7) 6.9±2.0 x106 
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cells/ml; p≤0.01), and compared to BRSV-Dk infected calves before ((PID -1) 
1.1±0.2 x106 cells/ml; p≤0.01) and after challenge ((PID 7) 0.8±0.7 x106 
cells/ml; p≤0.01). 
Both groups of calves demonstrated a shift in BAL cell type composition 
following challenge, from predominantly macrophages before infection 
((BRSV-Snk) 63.0±26.0%; (BRSV-Dk) 69.0±10.1%), to predominantly 
neutrophils after infection ((BRSV-Snk) 79.0±4.4%; (BRSV-Dk) 80.3±6.0%). 
4.3.2 Further characterization of the BRSV-Snk infection model in calves with 
BRSV-specific maternal antibodies (Papers III and IV) 
The infection model and the BRSV-Snk inoculum were verified to also be 
effective in calves with specific MDA and were further characterized, using 
data and samples collected from unvaccinated calves challenged in the 
experiment described in paper IV (calves d1-d5, Table 3). These calves had 
moderate titers of serum specific MDA (moderate MDA; mean±SD 2.0±0.2 
log10 titer) at the time of experimental infection. Corresponding data and 
samples from three uninfected calves were used as control (calves D1-D3, 
Table 3). 
Calves with moderate MDA were severely affected after aerosol inhalation 
of virulent BRSV (BRSV-Snk, 104.0 pfu), comparable to that observed in 
BRSV-Snk infected calves with very low levels of specific MDA (low MDA) 
and without prior priming (calves A2 and A3, paper III). 
Clinically, mild to moderate signs were first noticed on PID 3 and 4 in 
calves with moderate MDA, including cough and nasal discharge. By PID 7, 
these mild signs had progressed to severe signs of upper and lower respiratory 
disease, including: severely depressed general state with reduced or absent 
appetite; pyrexia (mean max 40.8°C; range 40.2-41.2°C); tachypnea (mean 
max±SD 81.6 SD±4.6 breaths/min) with moderate to severe abdominal 
dyspnea and wheezing lung sounds. 
Virus shedding in nasal secretion in infected calves with moderate MDA 
coincided with onset of clinical signs (PID 3), but peaked on PID 5 (mean±SD 
2.2±0.36 log10 TCID50 eq.), and was declining on PID 7 (mean±SD 1.1±0.74 
log10 TCID50 eq.) In the lower airways, high amounts of viral RNA was 
detected in BAL cells collected from control calves on PID 7 (mean±SD 
5.0±0.62 log10 TCID50 eq.), and live BRSV was isolated from these BAL cells 
(in passage one or two). 
At gross post-mortem examination, infected calves with moderate MDA 
had massive consolidated lung lesions, involving 36-64% of the lung tissue, 
and in addition, two calves (d3 and d4) had moderate lung pleural 
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emphysemas. Consolidated lung lesions were dark red and dense, mainly 
located in the cranioventral lobes. 
Lung tissue samples from consolidated areas were collected for 
histopathological examination, in each of the lobes in the right lung, from 
infected calves with moderate MDA. These exhibited severe inflammation 
microscopically (score 2.8-3.0, mean 2.9, scale 0-3), with severely affected 
lung parenchyma, including severe thickening of alveolar walls, lined with 
scattered type II-cells, and massive infiltration of inflammatory cells, mainly 
mononuclear and neutrophils. A few syncytial cells, as well as very few 
eosinophils, were observed. 
To further characterize inflammatory and immunological responses to 
experimental infection, post-mortem BAL samples collected from infected and 
uninfected calves were analyzed. Compared to identically collected BAL 
samples from uninfected controls, calves with moderate MDA demonstrated a 
significant elevation of total number of BAL cells after infection (1.1±0.2 x106 
cells/ml and 11.0±3.7 x106 cells/ml, respectively; p≤0.005). As with the post-
infection influx of BAL cells observed in calves with low MDA infected with 
BRSV-Snk, BAL cells observed in calves with moderate MDA after challenge 
consisted predominantly of neutrophils (68.6±14.4%), followed by 
macrophages (27.8±13.0%) and lymphocytes (3.6±2.0%). Regardless of 
specific MDA status, very few eosinophils were seen when BAL cells were 
enumerated (<0.5%). 
Coinciding with this influx of neutrophils, supernatant from post-mortem 
BAL from infected calves contained significantly elevated concentrations of 
IFNγ when measured by ELISA, compared to that of uninfected calves 
(mean±SD 0.53±0.19 and 0.06±0.04 ng/ml, respectively; p≤0.005). In contrast, 
no significantly elevated concentrations of IL-4, IL-6, IL-8 and TNFα were 
detected in BAL supernatant, although IL-6 concentrations tended to be higher 
in infected calves, compared to those of uninfected controls (mean±SD 
9.47±2.07 and 5.68±2.32 ng/ml, respectively; p=0.08). Interestingly, the IFNγ 
concentration in BAL supernatant (collected in the left lung) from BRSV-Snk 
infected calves was inversely correlated with the extent of lung lesions in the 
left lung (r2=0.82, p≤0.05; Figure 8). 
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Figure 8. Correlation between IFNγ in BAL supernatant and extent of lung lesions, seven days 
after experimental BRSV infection of calves with moderate levels of maternally derived BRSV-
specific serum antibodies. Calves were challenged by aerosol inhalation with the Snook strain 
BRSV (BRSV-Snk), and seven days later lung lesions were recorded post-mortem, and 
bronchoalveolar lavage (BAL) was performed on the left lung. When concentrations of IFNγ 
(ng/ml) in BAL supernatant were measured by ELISA (x-axis), and lesions in the left lung were 
quantified by digital image analysis (% of whole left lung; y-axis), an inverse correlation was 
identified (r2=0.82, p≤0.05; solid line). The arrow represents the mean IFNγ concentration in BAL 
supernatant of three uninfected calves, sampled identically. 
The impact of infection on lung function in calves with moderate MDA 
infected with BRSV-Snk was evaluated by passive measurement of airway 
resistance and reactance using the forced oscillation technique, before and after 
challenge (on PID 0 and 6). Following challenge, infected calves demonstrated 
significantly decreased airway reactance (PID 0 and 6: 0.03±0.03 and -
0.02±0.04 kPa/L/s at 10Hz; p≤0.05) and a tendency of increased airway 
resistance (PID 0 and 6: 0.17±0.03 and 0.20±0.06 kPa/L/s at 10Hz; p=0.2). 
4.4 Evaluation of immunogenicity and protective efficacy of 
three DIVA-compatible vaccines - two formulations of a 
subunit vaccine and one gene-deleted live BRSV vaccine - 
in calves with BRSV-specific maternal antibodies (Paper IV) 
In paper IV, we used the BRSV infection model presented in paper III to 
evaluate three DIVA-compatible vaccine candidates, derived from previous 
studies by the three project partners in this thesis work. 
A composition of recombinant subunits containing HRSV proteins P, M2-1 
and self-assembling nanorings of the HRSV protein N with recombinantly 
grafted epitopes from BRSV proteins F and G, was formulated with either the 
oil emulsion Montanide ISA71VG (SUMont) or ISCOM matrices, AbISCO-300 
(SUAbis). Both subunit vaccines were administered twice parenterally with an 
interval of three weeks, SUMont intramuscularly and SUAbis subcutaneously, 
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to be consistent with routes used in preceding experiments (Hägglund et al. 
2004; Riffault et al. 2010). In addition, one recombinant live BRSV with the 
SH gene deleted (∆SHrBRSV) was administered once intranasally. Four 
groups of five young calves with moderate titers of serum specific MDA (log10 
BRSV-specific IgG1 antibody titers: 1.9-3.3, mean 2.3) were each vaccinated 
with one of these three vaccines, or adjuvant alone (controls), and challenged 
by aerosol inhalation five weeks after first immunization. 
4.4.1 Clinical signs, virus shedding and lung pathology following challenge 
Unvaccinated control calves were severely affected after BRSV challenge 
All unvaccinated control calves were severely affected following challenge, as 
described in detail in section 4.3.2 and in paper IV; with severe respiratory 
clinical signs (accumulated clinical score, ACS; mean±SD 73.2±29.1) and high 
titers of virus in nasal secretion following challenge (accumulated virus shed, 
AVS; mean±SD 11.0±2.2 log10 TCID50 eq.), and extensive lung lesions at post-
mortem (mean±SD 48.3±12.0%). 
Calves immunized once intranasally with ∆SHrBRSV were highly protected 
from BRSV infection 
In contrast to control calves, calves immunized with ∆SHrBRSV and 
challenged with BRSV-Snk five weeks later, developed only very mild signs of 
respiratory disease, with a mean accumulated clinical score of 3.7 (SD±3.6). 
One calf (a1) had no clinical signs, one calf (a5) had mild dyspnea and slight 
wheezing lung sounds on PID 7, whereas clinical signs in the remaining calves 
(calves a2-a4), included coughing on provocation, slight serous nasal 
discharge, and slightly enhanced lung sounds, and were restricted to PID 6 and 
PID 7. Throughout the challenge, none of the calves immunized with 
∆SHrBRSV exhibited depression, loss of appetite, or rectal temperatures 
exceeding 39.6°C, and their mean maximum respiratory rate was 49.6 
breaths/min (SD±3.6 breaths/min).  
Only 2/5 calves immunized with ∆SHrBRSV shed virus in nasal secretion 
following challenge, and only in low quantities detected by RT-qPCR (max 
mean±SD 0.1±1.1 log10 TCID50 eq.), and for only 2 and 3 days in calves a3 and 
a5, respectively. The accumulated virus shed in ∆SHrBRSV-immunized calves 
(mean±SD 1.4±2.2 log10 TCID50 eq.) was nine logs lower than that of controls. 
Live virus could not be isolated (after three passages) and only low amounts of 
viral RNA were detected in BAL collected on PID 7 (mean±SD 2.1±0.6 log10 
TCID50 eq.), which was significantly less than that of controls (p≤0.001). 
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∆SHrBRSV-immunized calves had the least gross lung lesions (3.9±3.6%), 
and the least severe histopathological inflammation (score 0.8-2.3, mean 1.3) 
in sampled lesions, compared to all other groups of calves. Furthermore, 
∆SHrBRSV-immunized calves had significantly reduced concentrations of 
cells in BAL (mean±SD 5.2±3.5 cells x 106/ml) collected on PID 7, compared 
to controls (mean±SD 11.0±3.7 x106 cells/ml; p≤0.01). 
Calves immunized twice intramuscularly with SUMont were well protected 
against BRSV infection 
The clinical signs observed in SUMont-immunized calves following 
challenge were intermediate to the severe signs described for control calves 
and the very mild signs described for ∆SHrBRSV-immunized calves. The 
mean accumulated clinical score of SUMont-immunized calves was 18.0 
(SD±14.0). Mild clinical signs were first observed in SUMont vaccinated 
calves on PID 3, and peaked with moderate signs on PID 6, including 
spontaneous coughing, serous nasal discharge, slight wheezing lung sounds, 
slight to moderate dyspnea and elevated respiratory rate (mean max±SD 
54.4±8.3 breaths/min). Throughout the challenge, only 2/5 SUMont-
immunized calves had rectal temperatures ≥39.6°C, and only on one day each 
(calf b2: 39.9°C on PID 4; calf b4: 39.7°C on PID 2). 
Compared to controls, SUMont-immunized calves shed seven logs less 
virus in nasal secretion following challenge (accumulated, mean±SD 3.6 ± 2.6 
log10 TCID50 eq.), but two logs more than ∆SHrBRSV-immunized calves. In 
the lower airways, virus could only be isolated from BAL (PID 7) from one 
SUMont-immunized calf (b3, 3rd passage), and amounts of viral RNA 
(mean±SD 3.2±1.3 log10 TCID50 eq.) were significantly reduced compared to 
control calves (p≤0.001), but one log higher than those of ∆SHrBRSV-
immunized calves.  
Similarly, the extent of lung lesions recorded at post-mortem in SUMont-
immunized calves (8.8±10.2%), was significantly reduced compared to control 
calves (p≤0.05), but more extensive than those of ∆SHrBRSV-immunized 
calves. Histologically, SUMont-immunized calves demonstrated similar 
lesions, with similar severity (score 0.6-2.5, mean 1.6), compared to that 
described for ∆SHrBRSV-immunized calves. Compared to controls, calves 
immunized with SUMont had less cells in BAL on PID 7 (mean±SD 3.1±1.8 
cells x 106/ml; p≤0.01). 
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Calves immunized twice subcutaneously with SUAbis were afforded limited 
protection against BRSV infection 
Clinical signs observed in SUAbis-immunized calves following challenge 
were less severe than those observed in control calves, but more severe than 
those observed in calves immunized with SUMont, which was reflected in the 
intermediate accumulated clinical score (mean±SD 31.0±15.0). The nature of 
clinical signs observed in SUAbis-immunized calves were similar to those 
described for calves immunized with SUMont, but with higher mean peak 
respiratory rate (61.0±6.8 breaths/min) and rectal temperatures (3/4 calves 
≥39.7°C). 
SUAbis-immunized calves shed three logs less virus in nasal secretion 
(mean AVS±SD 7.9±3.4 log10 TCID50 eq.), compared to controls, but four logs 
more than SUMont (p≤0.05), and six logs more than ∆SHrBRSV-immunized 
calves (p≤0.005). Viral RNA was detectable in nasal secretion from calves 
immunized with SUAbis from PID 3 to PID 7 (mean 4.5 days). Live virus was 
isolated from BAL cells from 3/4 SUAbis-immunized calves in the third 
passage, compared to 5/5 in the first or second passage for control calves. 
Similarly, less viral RNA was detected in BAL from SUAbis-immunized 
calves (mean±SD 4.2±1.2 log10 TCID50 eq.) compared to controls, although 
this was not significant (p=0.07). 
On PID 7, calves immunized with SUAbis had extensive consolidated 
lesions in the lungs (mean 20.5±8.8%), although significantly less extensive 
than those of controls (p≤0.05). Histological lesions were moderate to severe 
(score 2.0-3.0, mean 2.5), but morphologically similar to the severe lesions 
described for controls. Compared to controls, calves immunized with SUAbis 
had significantly lower concentrations of cells in BAL on PID 7 (mean±SD 
3.2±1.9 cells x 106/ml; p≤0.01). 
 
 
 67 
 
Figure 9. Agreement between clinical signs, lung pathology and virus shed in nasal secretion, 
when calves were experimentally infected after prior immunization. Four groups of five calves 
were immunized with one of three formulations (as described in section 3.4.2): ∆SHrBRSV, 
SUMont, SUAbis, or adjuvant alone (Control). One SUAbis vaccinated calf was euthanized, due 
to traumatic injury. Five weeks after first immunization, all remaining calves were challenged by 
aerosol inhalation with BRSV-Snk. Clinical signs were scored and BRSV RNA in nasal secretion 
quantified for seven days following challenge, when accumulated clinical scores (x-axis) and 
virus shed (y-axis) was calculated (indicated by the center of each pie-chart). Extent of gross lung 
lesions (%) was quantified post-mortem, and is indicated by the gray portion of each pie-chart. 
4.4.2  Order of degree of vaccine-induced protection 
The different extent to which the three vaccinated groups of calves were 
affected by BRSV infection is illustrated in Figure 9, showing mean 
accumulated clinical scores and viral shed in nasal secretion, and mean extent 
of lung pathology. Figure 9 reveals a clear order of degree of vaccine-induced 
protection among groups, compared to controls: 
1. ∆SHrBRSV (once i.n.) induced a high level of protection 
2. SUMont (twice i.m.) afforded good protection 
3. SUAbis (twice s.c.) offered limited protection 
This order of degree of vaccine-induced protection from disease and virus 
replication, compared to controls, is supported in Figure 10, showing 
statistically significant differences in: (i) daily and accumulated clinical scores; 
(ii) macroscopic extent of lung lesions; (iii) histopathological severity of lung 
lesions; (iv) daily and accumulated virus titers detected by RT-qPCR in nasal 
secretion; and (v) virus titer in BAL on PID 7. The same relative order was 
seen when calves were ranked based on the three parameters in Figure 9, and 
group total rank sums were calculated (see Figure 5 in paper IV). 
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Figure 10. Summary of statistically significant differences between groups of calves 
experimentally infected with BRSV, after prior vaccination. Four groups of five calves were 
immunized as described in section 3.4.2, with ∆SHrBRSV (A), SUMont (B), SUAbis (C) or 
placebo (D, Control). Five weeks after first vaccination, calves were challenged with BRSV on 
post-infection day (PID) 0, and monitored for seven days, until PID 7. For each group, means and 
standard deviations were calculated for: daily and accumulated clinical scores, daily and 
accumulated virus titers in nasal secretion, as well as in bronchoalveolar lavage on PID 7, 
detected by RT-qPCR, and macroscopical extent and histological severity of lung lesions. For 
each parameter, the figure lists groups, ranked based on group mean for each parameter, from 
high to low. Note however, that calves immunized with ∆SHrBRSV had the lowest mean/rank 
across all presented parameters, consistently followed by SUMont, SUAbis and placebo 
immunized calves, in that order. Vertical lines indicate statistically significant differences 
between groups, where p-values for dashed and solid lines are indicated in the figure.  
4.4.3 Immune responses to vaccination and experimental challenge 
This section present immunological results from paper IV, including: serum 
BRSV-specific IgG1, and antibodies directed against proteins F, G, N, P and 
M2-1, as well as virus neutralizing antibodies (Figure 6 in paper IV); local 
antibodies directed against total BRSV antigen (IgA and IgG1) and the N 
protein (IgA), in nasal secretion and in BAL (Figure 7 in paper IV); and 
BRSV-specific proliferation in circulating lymphocytes (Figure 8 in paper IV). 
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In addition, BRSV-specific proliferation and cytokine production in cells 
extracted from tracheobronchial lymph nodes at PID 7 were analyzed in 
controls and calves immunized with ∆SHrBRSV (Table 3 in paper IV). 
A single intranasal immunization with ∆SHrBRSV primed for strong 
anamnestic mucosal IgA and systemic neutralizing humoral responses and 
local IFNγ producing BRSV specific T cells 
Following vaccination but before challenge, no humoral or systemic cellular 
immune responses were detected in calves immunized with ∆SHrBRSV 
(p≤0.05). Local BRSV-specific cellular immune responses were not 
investigated before challenge. 
However, following challenge (PID 7) ∆SHrBRSV-immunized calves 
demonstrated rapid and significant increases in BRSV-neutralizing antibodies 
in serum (p≤0.001) and BRSV-specific IgA antibodies in nasal secretion 
(p≤0.05), compared to before challenge (PID 0). The post-infection increase in 
neutralizing antibodies in serum was also reflected in significant increases in 
protein specific IgG antibodies directed against F (p≤0.01), G (p≤0.01), N 
(p≤0.01) and M2-1 (p≤0.05), compared to controls. 
In addition, a significant BRSV-specific proliferative response was detected 
in restimulated tracheobronchial lymph node lymphocytes from ∆SHrBRSV-
immunized calves after challenge compared to controls (p≤0.05), with an 
increased proportion of BRSV-specific IFNγ-producing lymphocytes (FACS; 
CD4+ p≤0.05; CD8+ p=0.06; compared to lymphocytes from ∆SHrBRSV-
immunized calves stimulated with uninfected cell lysate), and significantly 
increased IFNγ concentrations detected in supernatant of BRSV-stimulated 
cells (ELISA; p≤0.05), compared to supernatant of BRSV-stimulated cells 
from controls. 
Thus, the high level of protection from disease and virus replication 
observed in ∆SHrBRSV-immunized calves following challenge appears to 
have been mediated by rapid anamnestic BRSV-specific immune responses, 
including local cellular responses, as well as local and systemic virus 
neutralizing humoral responses. 
Two intramuscular immunizations with SUMont induced IFNγ-producing T 
cell responses and non-neutralizing humoral responses directed against 
proteins N, P and M2-1 but not against F and G epitopes 
Already after first vaccination, calves immunized with SUMont demonstrated 
both cellular and humoral immune responses. Significant proliferative BRSV-
specific responses were detected in restimulated PBMCs from SUMont-
immunized calves, compared to controls and all other vaccinated calves 
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(p≤0.001), two weeks after first vaccination (one week before boost). Humoral 
responses following first vaccination consisted of modest increases in titers of 
serum IgG antibodies directed at proteins N, P and M2-1, but these increases 
were not statistically significant, and antibodies were not neutralizing virus. 
Furthermore, titers of BRSV-specific IgG1 antibodies in serum continued to 
decline after first vaccination, which may be explained by concurrently 
declining titers of specific MDA. 
The second SUMont vaccination boosted the responses described after first 
vaccination, with: (i) a significant BRSV-specific T cell proliferative response 
two weeks after second immunization (p≤0.05), now with significantly higher 
concentrations of IFNγ in the supernatant of BRSV-restimulated cells (p≤0.05), 
compared to BRSV-restimulated cells from all other calves; and (ii) 
significantly higher titers of serum IgG antibodies directed against proteins N 
(p≤0.001), P (p≤0.05) and M2-1 (p≤0.001) at PID 0, compared to controls. 
However, although the mean total BRSV-specific IgG1 antibody titer of 
SUMont-immunized calves was slightly elevated before challenge, compared 
to controls, these antibodies were not directed against proteins F or G, and 
were not neutralizing virus. In addition to systemic humoral responses, 
SUMont-immunized calves demonstrated significantly higher levels of BRSV-
specific IgA antibodies in nasal secretion after second vaccination, on PID 0, 
compared to all other calves (p≤0.005). 
Following challenge, titers of protein specific antibodies tended to plateau, 
and serum from SUMont-immunized calves were still not neutralizing virus, 
despite a continued increase of mean BRSV-specific IgG1 antibody in these 
calves. Mucosal BRSV-specific IgA antibodies were significantly elevated in 
BAL on PID 7, compared to controls (p≤0.001), as was IgA directed against 
the N protein, compared to controls and the other vaccinated calves (p≤0.001 
and p≤0.05, respectively). Cellular responses were not investigated after 
challenge in SUMont-immunized calves. 
In summary, the good level of protection observed in SUMont-immunized 
calves following challenge two weeks after second vaccination, was probably 
mediated by the strong systemic T cell responses characterized by IFNγ 
secretion, observed already before challenge. Although SUMont induced 
strong local and systemic BRSV-specific humoral responses, systemic humoral 
responses were non-neutralizing, and directed against the N, P and M2-1 
proteins, and not the F and G epitopes. 
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Two subcutaneous immunizations with SUAbis induced non-neutralizing 
humoral responses directed against proteins N, P and M2-1, but no T cell 
response 
Following first and second SUAbis vaccination, humoral immune responses 
detected in immunized calves were similar to those described for SUMont-
immunized calves, but with less amplitude, and there was no indication of 
induction of a cellular response. Specifically, titers of serum IgG antibodies 
against N, P and M2-1 were all significantly elevated after challenge, 
compared to controls (p≤0.001, p≤0.05, p≤0.001, respectively). However, sera 
from SUAbis-immunized calves did not neutralize virus. 
The limited protection observed in SUAbis-immunized calves was thus 
paralleled by equally limited protective immune responses: with an absence of 
neutralizing antibodies, which were prominent in ∆SHrBRSV-immunized 
calves, and an absence of T cell responses, which were detected in SUMont-
immunized calves. 
4.4.4 Vaccine safety  
∆SHrBRSV was appropriately attenuated and did not transmit to seronegative 
sentinel calves 
Calves immunized once intranasally with ∆SHrBRSV and co-housed 
seronegative sentinel calves were monitored clinically, serologically and 
virologically following vaccination. Transmission of ∆SHrBRSV to sentinels 
was ruled out by: the absence of clinical signs of infection; the absence of 
BRSV RNA in nasal secretion; and the absence of BRSV-specific humoral 
responses three weeks after co-housing with ∆SHrBRSV vaccinated calves. 
Furthermore, calves vaccinated with ∆SHrBRSV showed only very slight 
upper respiratory signs following vaccination and shed no (4/5 calves), or 
marginal amounts (calf a2; ≤0.36 TCID50 eq. unit; 5-7 days post-vaccination), 
of virus in nasal secretion. 
Subunit vaccines were safe and did not induce any severe adverse reactions to 
vaccination 
Calves immunized twice parenterally with SUMont, SUAbis or placebo 
vaccine, were clinically monitored following first and second vaccination, with 
special attention to possible swellings at injection sites. 
Following vaccination with SUMont, calves demonstrated elevated rectal 
temperature (mean calf max±SD 40.8±0.29°C and 40.0±0.11°C, 1st and 2nd 
vaccination, respectively) and slight depression, with no or mild local 
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swellings after first vaccination, and moderate to marked local swellings after 
second vaccination. These adverse reactions waned within 2-3 days. 
Calves immunized with either SUAbis or adjuvant alone demonstrated 
elevated rectal temperatures following first (mean max±SD 40.0±0.5°C), but 
except for one control calf (d5, max 40.1°C), no temperature elevations 
following second vaccination. Following both vaccinations, but more 
pronounced after first vaccination, these calves developed mild to moderate 
swellings at injection sites, which persisted for 2-3 days. 
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5 Discussion 
The development of BRSV vaccines that can effectively induce long lasting 
protection in young calves with BRSV-specific maternally derived antibodies 
(MDA) remains a high priority to the cattle industry. 
Disease is commonly seen in calves less than 1 year old, with a peak in 
morbidity between 1-3 months (Verhoeff et al. 1984). Young immunologically 
immature calves may be afforded some protection from BRSV infection by 
MDA (Chase et al. 2008; Kimman et al. 1988). However, as for many 
pathogens in veterinary and human medicine, specific MDAs often completely 
suppress antibody production and at least partially inhibit induction of humoral 
memory following vaccination or natural exposure, whereas cellular memory 
and responses are usually minimally affected (Kimman, Westenbrink, 
Schreuder, et al. 1987; Niewiesk 2014). For many commercial BRSV vaccines, 
MDA suppression of vaccine responses often results in insufficient immune 
responses when calves are experimentally or naturally exposed to virulent 
BRSV (Larsen et al. 2001; Hägglund et al. 2004). 
Vaccination programs using commercially available BRSV vaccines 
interfere with epidemiological surveys, because the humoral responses induced 
by classic vaccines are indistinguishable from those induced by natural 
infection. New generation DIVA vaccines that omit at least one immunogenic 
viral protein in the rational vaccine design allow continued serological 
monitoring, and the ability to monitor vaccine safety and efficacy in the field. 
Classic BRSV-ISCOMs have previously been shown to overcome the 
suppressive effect of specific MDA in older calves (7–15 weeks old) 
(Hägglund et al. 2004). In this thesis work, BRSV-ISCOMs were evaluated in 
younger calves (3–8 weeks old), and the vaccine formulation was characterized 
with regard to immunogenicity and protein content. 
In addition, three DIVA-compatible new generation BRSV vaccines were 
evaluated in a severe BRSV calf infection model described in this thesis. 
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5.1 BRSV-ISCOMs overcame the suppressive effect of 
maternally derived antibodies and induced protective 
antibody and T cell responses in young calves (Paper I) 
In agreement with previous results in older calves (Hägglund et al. 2004), the 
BRSV-ISCOMs evaluated in paper I overcame the suppressive effect of MDA 
in younger calves and induced a high level of clinical and virological 
protection following challenge. Protection observed in BRSV-ISCOM-
immunized calves was associated with strong humoral responses and a Th1-
oriented T cell response, which in turn was strongly linked to the ISCOM 
adjuvant, as calves immunized with BRSV proteins without adjuvant were 
significantly less well protected. These results suggest that BRSV-ISCOM 
vaccination can be effective in immunologically immature calves with specific 
MDA, which is relevant in field conditions. Additionally this suggests that 
BRSV-ISCOMs are safe in this target group, as no exacerbated disease 
following challenge was observed clinically or on investigation of pulmonary 
histopathology post-mortem. 
BRSV-ISCOM-immunized calves demonstrated only limited respiratory 
signs and minimal lung pathology following challenge, in contrast to calves 
immunized with adjuvant alone or with PBS, which showed moderate to severe 
respiratory signs and moderate lung lesions. 
The virological protection was even more effective, with no or only 
marginal virus RNA detected in nasal secretion from BRSV-ISCOM-
immunized calves, and a mean area under curves of virus shed in nasal 
secretion from PID 0 to PID 6 (AVS) seven logs higher in all other calves. 
 Protection in BRSV-ISCOM-immunized calves was associated with strong 
anamnestic mucosal BRSV-specific IgA responses after challenge, despite 
nominal levels of specific IgA in serum and nasal secretion before challenge, 
indicating strong priming by BRSV-ISCOMs. In addition, elevated levels of 
BRSV-specific IgA antibodies were detected in lung lavage from BRSV-
ISCOM-immunized calves six days after challenge, and correlated with 
protection within that group. The ability to mount a strong and rapid mucosal 
IgA response has previously been associated with protection (Kimman, 
Westenbrink, Schreuder, et al. 1987). 
Elevated levels of BRSV-specific IgG (IgG1 and IgG2) in serum and nasal 
secretion were observed already before challenge in BRSV-ISCOM-
immunized calves. Acquired or maternally derived pre-existing neutralizing 
antibodies in nasal secretion appeared to be protective against BRSV infection 
in one study (Mohanty et al. 1976). This suggests that nasal IgG in BRSV-                            
- 
 75 
ISCOM-immunized calves may have contributed to protection, although the 
virus neutralizing capacity of nasal secretion was not investigated. 
To approximate the neutralizing capacity of sera from immunized calves 
before challenge, serum mAb 19 competitive antibodies were quantified. Like 
with the commercially available humanized monoclonal antibody palivizumab 
for HRSV (Wu et al. 2005), mAb 19 binds to antigenic site IV on the F protein 
and neutralizes BRSV in vitro (Arbiza et al. 1992). Palivizumab competitive 
ELISAs are increasingly used in HRSV studies (Swanson et al. 2011; Smith et 
al. 2012), because these assays are less time-consuming and less costly, as well 
as being easier to standardize between different laboratories, compared to virus 
neutralization assays. One of these ELISAs has been shown to be indicative of 
neutralizing capacity of antibodies as the results correlate with a virus 
neutralization assay (Glenn et al. 2013). Further studies are needed to confirm 
such a correlation for BRSV and mAb 19. However, sera from BRSV-ISCOM-
immunized calves did compete with mAb 19 (paper II), and were later 
confirmed to neutralize virus in a plaque reduction assay (data not shown), 
with titers similar to those previously reported for older BRSV-ISCOM-
immunized calves (Hägglund et al. 2004). 
Vaccine-induction of cytolytic CD8+ T lymphocyte (CTL) activity and 
CD4+ T helper cell cytokine production, which further stimulates both humoral 
and cellular responses and the generation of memory, are important in the 
combined immune response to BRSV infection (Taylor et al. 1995). In mice, 
modification of APCs, through CD40/CD40L binding by antigen specific 
CD4+ T helper cells, induce necessary co-stimulation by APCs, to activate 
antigen specific naïve CD8+ T cells, and to generate CTL immunity and 
memory (Clarke 2000), which could further explain why CD4+ T helper cell 
responses are important in the initial response to BRSV in calves (Thomas et 
al. 1996). 
Restimulated PBMCs from BRSV-ISCOM-immunized calves proliferated 
and produced both IL-4 and IFNγ, with a predominance of IFNγ. This is in line 
with previous studies using classic ISCOMs to immunize mice (Villacres-
Eriksson et al. 1992; Maloy et al. pr1995; Sjölander et al. 1997), and suggests 
that a Th1 type immune response, dominated over a Th2 type immune response 
in mice (Zhu & Paul 2008), although cattle may have less Th1/Th2 polarized 
immune responses (Brown et al. 1998). These cellular responses likely 
contributed to the protection observed in BRSV-ISCOM-immunized calves, 
and extend findings from a previous study (Hägglund et al. 2004) in which 
cellular responses unfortunately were not investigated.  
Inactivated virus used in the lymphocyte proliferation assay in paper I 
mainly stimulates CD4+ T helper cells, and not CD8+ T cells. However, CTLs 
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were likely primed in vivo by BRSV-ISCOM immunization, supported by the 
prominence of the IFNγ producing CD4+ T helper cell population, as 
demonstrated in vitro. Nonetheless, better characterization of cellular responses 
is desirable, and could be achieved through isolation and specific assaying of 
PBMC subpopulations, such as measurement of the cytolytic activity of 
isolated CD8+ T cells through flow cytometry of co-cultured autologous target 
cells (e.g. B cells) pulsed with relevant antigen (Mbitikon-Kobo et al. 2012). 
The strong humoral and cellular immune responses observed in BRSV-
ISCOM-immunized calves demonstrate that BRSV-ISCOMs overcame the 
commonly observed inhibitory effect of MDA on vaccine-induced immune 
responses. 
Even low levels of serum specific MDA may completely suppress humoral 
responses, and may attenuate subsequent memory responses. This has been 
shown for BRSV and HRSV (Kimman, Westenbrink, Schreuder, et al. 1987; 
Crowe et al. 2001) and many other pathogens and vaccines, e.g. in infant 
vaccination against measles, a virus in the same family as RSV, 
Paramyxoviridae (Bertley et al. 2004; Gans et al. 2004). 
The suppressive effect of specific MDA on B cell activation and antibody 
production are mainly mediated by two mechanisms: epitope masking and 
cross-linking of receptors on B cells (Niewiesk 2014). 
Suppression by epitope masking is suggested to work by specific MDA 
binding to vaccine antigen, thereby physically blocking access by B cells 
(Karlsson et al. 1999). This problem might be partially overcome by increasing 
the amount of antigen(s) in the vaccine, as demonstrated by effectiveness of 
high titer measles vaccination in young children (Whittle et al. 1988). 
However, this approach was also shown to be harmful to individuals with low 
levels of specific MDA (Garenne et al. 1991), and may be detrimental to the 
induction of immune memory (Kalia et al. 2006). Additionally, high titer 
vaccines are costly to produce.  
Complexes of multimeric antigen and pre-existing antibodies can interfere 
with B cell receptor (BCR) oligomerization and signaling, through cross-
linking of BCRs and FcγIIB receptors (Liu et al. 2010). However, inhibition by 
cross-linking of receptors has been shown to be limited using small multimeric 
antigen carriers (Enriquez-Rincon & Klaus 1984), which might explain how 
BRSV-ISCOMs (56 nm mean diameter) avoided inhibition by MDA. 
 In addition, specific antibodies bound to a small multimeric antigen carrier 
(in the Å range) have been suggested to enhance uptake by APCs, and 
stimulation of APC maturation (Enriquez-Rincon & Klaus 1984; Getahun & 
Heyman 2006), a mechanism reported for monomeric antigen/antibody 
complexes (Schnurr et al. 2005). Internalization of classic ISCOMs by APCs is 
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partially mediated by the hydrophobicity of ISCOM particles, but may be 
enhanced by specific receptor interaction between ISCOM protein and APC 
surface protein (Villacres et al. 1998; Lövgren Bengtsson et al. 2011). Whether 
the presence of specific antibodies can enhance APC uptake of classic ISCOMs 
requires further studies. 
Nonetheless, in the challenge infection of paper I, BRSV protein formulated 
with ISCOMs (BRSV-ISCOMs) overcame the suppressive effect of maternal 
antibodies and induced IgG antibody production, IgA memory, and Th1 type 
cellular responses, in contrast to calves immunized with BRSV proteins alone. 
This demonstrates that the adjuvant formulation played an essential role in the 
induction of protective immunity by BRSV-ISCOMs. 
Thus, as BRSV-ISCOM vaccination successfully protected young calves 
with specific MDA against BRSV infection, and have previously been shown 
to induce protection exceeding that induced by a commercially available 
inactivated vaccine (Hägglund et al. 2004), this formulation is a very promising 
vaccine candidate. Characterization of BRSV-ISCOMs would facilitate batch-
to-batch consistency of this vaccine, and provide knowledge that could be used 
in future rational vaccine design. 
5.2 Characterization of BRSV-ISCOMs verified high 
concentrations of BRSV proteins F and N, and additionally 
identified BRSV proteins G, M, M2-1, P and SH, as well as 
further elucidated BRSV-ISCOM-induced immune 
responses (Paper II) 
The protein makeup of BRSV-ISCOMs used in paper I was investigated in 
paper II, using gel electrophoresis, Western blot, dot blot and mass 
spectrometry (MALDI-TOF and LC-MS/MS). Each dose of BRSV-ISCOMs 
contained 188 µg of protein, consisting of approximately 77 µg F protein, 17 
µg of N protein, and BRSV proteins G, M, M2-1, P and SH probably at lower 
concentrations, as well as several cell-derived proteins. BRSV proteins L, NS1, 
NS2 and M2-2 were not detected in the BRSV-ISCOMs used in paper I, even 
by the highly sensitive LC-MS/MS method (Smith et al. 2004). 
A previous study in which HRSV-ISCOMs were prepared by dialysis, like 
BRSV-ISCOMs in paper I and II, identified the F and G proteins in HRSV-
ISCOMs (Hu et al. 1998), whereas the F and N protein were identified in 
BRSV-ISCOMs prepared by ultracentrifugation (M. Trudel et al. 1989). The F 
protein was the most abundant protein in both BRSV- and HRSV-ISCOMs (M. 
Trudel et al. 1989; Hu et al. 1998). Thus, results in paper II confirmed previous 
findings regarding classic RSV-ISCOMs, and also enhance our understanding 
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of the makeup, of these vaccines by semi-quantification of these proteins and 
identification of BRSV proteins M, M2-1, P and SH, and cell-derived proteins 
in BRSV-ISCOMs. 
Additionally, sera from BRSV-ISCOM-immunized calves in paper I were 
analyzed to determine to which BRSV proteins antibodies were directed. As 
expected, based on the high concentrations of proteins F and N in BRSV-
ISCOMs, and the known immunogenicity of these proteins (Walsh et al. 1987; 
Riffault et al. 2010), significantly elevated titers of serum antibodies against 
proteins F and N were detected in BRSV-ISCOM-immunized calves. 
Similarly, the highly immunogenic glycoprotein G (Walsh et al. 1987; Taylor 
et al. 1997) induced G-specific serum antibodies in BRSV-ISCOM-immunized 
calves. Antibodies against the SH protein were also elevated in BRSV-
ISCOM-immunized calves, compared to calves immunized with BRSV 
proteins alone or PBS, but not compared to calves immunized with adjuvant 
alone, which may be explained by individual variations in levels of specific 
MDA. Proteins P and M, detected at low concentration in BRSV-ISCOMs, did 
not appear to induce specific antibodies.  
The individual contribution of each detected protein to BRSV-ISCOM-
induced protection cannot be unequivocally identified based on available data. 
However, previous studies have shown that the glycoproteins F and G induce 
neutralizing serum antibodies and mucosal IgA antibodies (Westenbrink et al. 
1989; Walsh et al. 1987; Taylor et al. 1997; Taylor et al. 2005), and that the F 
protein activate CD8+ CTLs (Gaddum et al. 2003). Other studies have shown 
that while proteins N, M2-1 and P induce non-neutralizing antibodies (Riffault 
et al. 2010; paper IV), importantly these proteins have epitopes recognized by 
CD8+ CTLs (Gaddum et al. 2003; Taylor G., personal communication). 
Antibodies directed against the SH protein do not neutralize virus in vitro, but 
have been shown to reduce virus replication in HRSV-infected mice, likely by 
connecting SH on the surface of infected cells to Fcγ receptors of alveolar 
macrophages (Schepens et al. 2014). In that study, protection from subsequent 
HRSV infection of SH immunized mice was concluded to be antibody 
mediated, since, although a mouse CD4+ T cell epitope within the SH protein 
has been reported (Nicholas et al. 1989), no SH specific T cells were detected 
in vaccinated mice,. In this context, the BRSV-ISCOM-induced protective 
humoral and cellular responses observed in paper I may have been mediated by 
antibodies against proteins F (including antibodies competing with the 
neutralizing mAb 19), G and SH, and T cell responses against F, N, M2-1 and 
P. 
The role of the cell-derived proteins detected in BRSV-ISCOMs is not 
known. These proteins may have adjuvant effects, but could also potentially 
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cause hypersensitivity and a Th2 type immune response in some individuals 
when administered repeatedly to calves, similar to that observed in mice 
inoculated with vaccine and HRSV inoculum containing residual bovine 
proteins (Ostler & Ehl 2002). However, there are likely residual cellular 
proteins in many commercial bovine vaccines, and the low frequency of 
reports of immunopathology in vaccinated cattle might be explained by 
differences in immune responses between cattle and mice (Brown et al. 1998). 
Nonetheless, although there was no clinical or histopathological indication of 
immunopathology in BRSV-ISCOM-immunized calves, the role of cellular 
proteins in this formulation deserves further investigation in extended studies, 
to minimize the risk of immunopathology in certain individuals. 
The adjuvant formulation in BRSV-ISCOMs considerably enhanced 
protective immune responses, as demonstrated by the absence of similar 
responses and the poor virological protection induced by BRSV proteins alone. 
Classic ISCOMs have been shown to induce Th1 type cellular and humoral 
immune responses in mice (Villacres-Eriksson et al. 1992; Maloy et al. 1995; 
Sjölander et al. 1997), similar to those observed following BRSV-ISCOM 
vaccination of calves in paper I. ISCOMs recruit innate and adaptive effector 
cells to lymph nodes draining the site of subcutaneous vaccination, including 
IFNγ-producing NK cells, which activate dendritic cells (DCs) (Duewell et al. 
2011). Following ISCOM-mediated uptake by DCs and B cells, antigen is 
processed and epitopes presented on major histocompatibility complex (MHC) 
class II molecules, which may activate specific CD4+ T helper cells, and on 
MHC class I molecules through cross presentation, which may activate specific 
CD8+ T cells (Robson et al. 2008; Schnurr et al. 2009). Although in paper I 
(when isolated PBMCs were restimulated with inactivated virus), only CD4+ T 
helper cells were stimulated in vitro, specific CD8+ T cells were also likely 
stimulated in vivo by BRSV-ISCOM immunization, as discussed earlier. 
Membrane proteins readily associate with ISCOM particles (Morein et al. 
1984), as do some internal viral proteins (M. Trudel et al. 1989; Polakos et al. 
2001), depending on their relative hydrophobicity, and possibly through 
association with other proteins. Whether the proteins detected in the BRSV-
ISCOM formulation in paper I were incorporated or associated with the 
ISCOM particles was not confirmed. However, this could be investigated by 
fractioning of the formulation by ultracentrifugation through a sucrose 
gradient, followed by analysis of lipid and protein content in each fraction. 
In conclusion, the classic BRSV-ISCOM formulation evaluated in paper I 
overcame the suppressive effect of MDA, and induced a high level of clinical 
and virological protection. Strong humoral responses against proteins F and N, 
present at high concentrations in BRSV-ISCOMs, and in addition G and SH, 
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detected in low concentrations, were induced by BRSV-ISCOMs. Proteins P, 
M and M2-1, detected at low concentrations, did not induce significant 
humoral responses, but may have induced CD4+ or CD8+ T cell responses, 
although protein-specific T cell responses were not evaluated. 
To be cost-effective and to ensure batch-to-batch consistency, large-scale 
propagation of BRSV and commercialization of classic BRSV-ISCOMs would 
require optimization of the described protocol. Alternatively, large-scale 
production of individual recombinant viral proteins is a viable option as it has 
become easier and less costly, and additionally facilitates rational design of the 
protein content and adjuvant used in the vaccine. 
5.3 Merging methods from different laboratories produced a 
robust BRSV challenge model with high clinical expression 
in calves with passive immunity (Paper III & IV) 
Information about the protein content in the BRSV-ISCOMs and 
preliminary results from separate vaccine evaluations performed by two other 
project partners in this thesis work, resulted in three vaccine candidates that 
warranted further evaluation. 
The three involved research groups had previously carried out experimental 
BRSV infections to evaluate vaccines in calves of varying age and levels of 
specific MDA, using: (i) aerosol inhalation of BRSV-Dk, in genetic subgroup 
II (Valarcher et al. 2000), propagated in cell culture (paper I); (ii) i.n. 
nebulization and i.t. injection of the BRSV-3761 isolate, in genetic subgroup V 
(Meyer et al. 2008), passaged three times in neonatal calves, and recovered in 
each passage by BAL (Riffault et al. 2010); and (iii) similar to (ii), except the 
inoculum was BRSV-Snk, in genetic subgroup IV (Valarcher et al. 2000), 
passaged in gnotobiotic calves (Taylor et al. 2014a). 
These experiments were in turn based on previously published studies, e.g. 
(Tjørnehøj et al. 2003; Hägglund et al. 2004; Taylor et al. 1995). In addition to 
the differences in inocula and mode of inoculation, the three laboratories had 
used different methods to monitor key outcomes of experimental infection. 
Therefore, a common BRSV infection model in calves was developed, with 
the aim of producing consistently high clinical expression, along with 
consolidated methods for monitoring infection, in order to evaluate these three 
vaccines, and to enable comparability with follow-up studies performed in the 
different laboratories (e.g. studies on duration of immunity, or evaluation of 
heterologous prime/boost regimens). 
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Two groups of three calves were experimentally infected with BRSV; either 
BRSV-Snk (calves A1-A3) passaged in calves, or BRSV-Dk (calves B1-B3) 
with low number of cell culture passages. Both inocula were administered by 
aerosol inhalation using identical facemasks, nebulizers and air compressors. 
Following challenge, regardless of inocula, all calves developed manifest 
BRSV disease, demonstrating that challenge by small droplet (≤5 µm) 
aerosolization of BRSV is effective in calves. How deep infectious BRSV 
reaches in the respiratory tract following aerosol inhalation by calves is 
unknown. One study using similar aerosol inhalation in combination with 
intratracheal injection to infect calves with BRSV reported that virus 
replication started in the upper airways, and progressed to the lower airways 
(Viuff et al. 2002). However, another study where cattle (9–12 month old) 
were infected with aerosolized foot-and-mouth disease virus, demonstrated 
simultaneous infection of the whole lung (Pacheco et al. 2010). Even if, as is 
the case in humans (Knight 1980), inhaled aerosol droplets reach the alveoli in 
calves, to the author’s knowledge there are no published data showing to what 
extent infectious BRSV virions are carried in small aerosol droplets. Future 
studies on this topic, and studies to further investigate the pathogenesis of 
natural versus different methods of experimental BRSV infection in calves, 
might shed light on these issues, as well as add an additional perspective on the 
clinical relevance of different BRSV infection models, such as the one 
presented in paper III. 
The BRSV-Snk inoculum was concluded to induce more severe disease, 
compared to the BRSV-Dk inoculum. BRSV-Snk-infected calves were 
consistently more severely affected by BRSV infection, across clinical, 
pathological and virological parameters. This difference in potency might 
simply be explained by differences in strain virulence, but may also have been 
influenced by passage and propagation in calves and in cell culture, for BRSV-
Snk and BRSV-Dk, respectively.  
Passage of BRSV-Dk in BT cells may have attenuated its virulence in 
calves, which would explain a higher level of clinical signs observed using the 
same inoculum with fewer passages (paper I), and when propagated in fetal 
lung cells (Hägglund et al. 2004). It is likely that changes in virulence 
following passage(s) in cell culture depend on the virus strain, cell type and 
number of passages. Some studies have demonstrated loss of virulence of 
BRSV or HRSV after passage in vitro (Deplanche et al. 2007; Kwilas et al. 
2009), whereas other studies have suggested that passage in cell culture 
induces no significant changes in the gene coding for the attachment protein 
(Furze et al. 1997; Larsen et al. 1998). 
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In contrast to BRSV-Dk, the BRSV-Snk inoculum was passaged and 
propagated in gnotobiotic calves. Passage of both inocula in either gnotobiotic 
calves or cell culture prior to experimental infection would have facilitated 
better comparability of the virulence of the two strains, but that was not 
feasible, nor was it needed for the purpose of the study in paper III. 
Following challenge, two out of three calves infected with BRSV-Snk 
(calves A2 and A3, Table 3) shed high amounts of virus in nasal secretion 
following challenge. The remaining calf (A1) shed considerably less virus in 
nasal secretion, and based on rapid seroconversion after BRSV-Snk 
inoculation, was subsequently determined to have been previously primed by 
natural BRSV infection.  
All BRSV-Snk-infected calves (including calf A1) demonstrated severe 
clinical signs and moderate to severe lung pathology following challenge, 
similar to that described for natural BRSV infection in the field (Bryson 1993; 
Verhoeff et al. 1984). Contrary to previous reports (Baker et al. 1986; Van der 
Poel et al. 1994), the prior exposure of calf A1 did not appear to provide 
clinical protection against experimental BRSV reinfection. 
The case of calf A1 illustrates that in the event of BRSV infection at a 
young age serum specific MDA can inhibit humoral responses despite 
establishment of immune memory, and that declining serum specific MDA 
titers can mask weak responses, which is in agreement with previous 
observations (Uttenthal et al. 2000; Kimman, Westenbrink, et al. 1989). 
Consequently, seromonitoring in herds delivering supposedly BRSV-naïve 
calves needs to be more stringent to conclusively rule out prior exposure. 
BRSV-Snk, but not BRSV-Dk infection was shown to induce a significant 
increase of cells in post-mortem BAL (predominantly neutrophils), compared 
to cells in BAL before challenge, which have previously been reported in 
naturally BRSV-infected calves (Kimman et al. 1986). This suggests a 
difference in strain virulence or kinetics of infection. 
A marked difference in virus localization between the two groups was 
revealed when BRSV antigens in sections of trachea and lung tissue were 
immunohistochemically stained post-mortem. This occurred despite virus  
isolation from BAL cells and high virus titers detected in BAL supernatant 
from all infected calves regardless of inocula (including calf A1). Abundant 
virus was observed in the lungs of BRSV-Snk-infected calves (except calf A1) 
and very little in the trachea, whereas the opposite was observed in BRSV-Dk-
infected calves. This might be explained by a difference between the two 
inocula in progression of virus replication on PID 7, given that virus replication 
starts in the upper airways and progresses to the lower airways (Viuff et al. 
1996). 
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The conclusion in paper III, that BRSV-Snk passaged in gnotobiotic calves 
was the most suitable inoculum for a BRSV infection model in calves, was 
confirmed when the model was repeated and further characterized in five 
unvaccinated calves (d1-d5) with moderate levels of specific MDA in the 
experiment described in paper IV. Following challenge with the BRSV-Snk 
inoculum in that experiment, calves d1-d5 demonstrated clinical signs and lung 
pathology similar, but even more severe, than that observed in calves A1-A3, 
and shed similar amounts of virus in the upper and lower airways.  
When BAL cells collected from calves d1-d5 seven days after challenge 
were enumerated, an influx of neutrophils was observed, similar to that 
observed in calves A1-A3. In addition, elevated concentrations of IFNγ in BAL 
supernatant at PID 7 were detected, whereas IL-4 was present only at minimal 
concentrations, which is in agreement with previous findings in primary 
infected calves (Grell, Tjørnehøj, et al. 2005). IFNγ can be produced by cells 
both in the innate immune system, such as neutrophils, NK cells, alveolar 
macrophages and γδT cells, and by cells in the adaptive immune system, such 
as CD8+ T cells (Mcinnes et al. 1999; Sohn et al. 2007; McGill et al. 2013). 
Thus, IFNγ detected in BAL supernatant might have been produced by CD8+ T 
cells, which migrate to the lungs during acute BRSV infection (Antonis et al. 
2006), or possibly by the increased numbers of neutrophils detected in BAL. 
Either way, this appeared to be a protective response, as there was an inverse 
correlation in calves d1-d5 between concentrations of IFNγ in BAL 
supernatant, and the macroscopic extent of lung pathology. 
In contrast to IFNγ, concentrations of TNFα, IL-6 and IL-8 were not 
elevated in calves d1-d5 in BAL collected seven days after challenge, although 
increased expression of these cytokines has been associated with BRSV 
infection in calves (Røntved et al. 2000; Grell, Riber, et al. 2005; Grell, 
Tjørnehøj, et al. 2005) and lambs (Redondo et al. 2014). This discrepancy may 
be related to differences in timing of sampling in relation to the progression of 
infection. 
Objective assessment of lung function to enable comparison between calves 
and between experiments is often limited to respiratory frequency. 
Auscultation of lung sounds, on the other hand, is subjective. Therefore the 
forced oscillation technique (FOT) was evaluated as a means to passively and 
objectively measure lung function during BRSV infection in calves. By using 
this technique the effect of BRSV infection on the respiratory function was 
demonstrated. FOT measurements in calves d1-d5, before and after challenge, 
indicated increased resistance and decreased reactance in the lower airways, 
which have been associated with bronchoconstriction and obstructive airway 
processes (Reinhold et al. 1996; Oostveen et al. 2003). Passive measurement of 
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airway resistance, using methods similar to FOT, have been used in mice 
(Davis et al. 2007) and infants (Drysdale et al. 2014) to assess the impact of 
HRSV on lung function, and could be an additional objective parameter when 
evaluating BRSV vaccines or therapeutics in calves. 
In brief, protocols and methods from different laboratories were 
consolidated and refined, and validated as a robust BRSV infection model, 
with high clinical expression in calves with maternal antibodies. In addition, 
tools to monitor and evaluate key outcomes of BRSV infection were 
developed. 
5.4 ∆SHrBRSV and SUMont induced almost complete and 
partial protection, respectively, through distinct 
immunological pathways (Paper IV) 
The evaluation in calves of three separate vaccines described in paper IV was 
the culmination of this thesis work and the product of encouraging results from 
three different project partners in developing killed vaccines, such as BRSV-
ISCOMs (Hägglund et al. 2004 and papers I & II) or N nanorings (Riffault et 
al. 2010), and live attenuated gene-deleted vaccines, such as ∆SHrBRSV 
(Taylor et al. 2014a). 
Formulation of the subunit vaccines was based on knowledge of BRSV 
proteins involved in generating a protective immune response and results from 
studies on BRSV-ISCOMs (paper I and II). Different recombinant proteins 
were obtained or generated, and included in the subunit composition. 
The nucleoprotein N was included as N nanorings, and because 
recombinant F and G proteins could not be obtained in sufficient quantity, 
known protective epitopes from BRSV F and G were attached to the N or C 
terminus of the HRSV N protein, producing epitope-decorated N nanorings 
(eN; Table 2). 
Recombinant HRSV P and M2-1 were also added to the subunit 
composition, as these proteins contain epitopes recognized by CTLs, and were 
also identified in BRSV-ISCOMs, as discussed earlier. 
The subunit composition was formulated into two vaccines: SUAbis, 
adjuvanted by ISCOM matrices (AbISCO-300), and SUMont, adjuvanted by 
an oil emulsion (Montanide ISA71VG). Both types of adjuvants have been 
shown to enhance T helper cell, CTL and antibody responses (Lövgren 
Bengtsson et al. 2011; Aucouturier et al. 2001). 
∆SHrBRSV, a live recombinant BRSV vaccine, attenuated by deletion of 
the SH gene, had been shown to be effective and sufficiently clinically 
attenuated in seronegative calves (Taylor et al. 2014a). Similarly, a 
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recombinant live SH-gene-deleted HRSV vaccine is one of the most promising 
vaccine candidates in clinical trials in children (Malkin et al. 2013). 
The SH protein was chosen as a common DIVA marker, and was omitted 
by rational design from all three vaccine candidates because it had been shown 
to be immunogenic (paper II), but non-essential to protection (Taylor et al. 
2014a). A common DIVA marker enables development and use of a single 
DIVA assay, and combined vaccination with successful candidates.  
The safety, immunogenicity and protective efficacy of these three vaccines 
were evaluated and compared in calves with specific MDA, using the regimen 
and route expected to be the most effective, and believed to comply with 
requirements in the field.  
∆SHrBRSV was administered once intranasally, five weeks before 
challenge, whereas the subunit vaccines were administered twice 
intramuscularly (SUMont) or subcutaneously (SUAbis), five and two weeks 
before challenge. Controls received ISCOM matrices alone, twice at three 
weeks of interval. 
Immunization with these three vaccines offered different levels of 
protection against BRSV infection, clearly and consistently distinct from each 
other. Protection induced by ∆SHrBRSV and the subunit vaccines, 
respectively, was mediated by dissimilar immune responses. 
Unvaccinated calves (d1-d5) all showed signs of general depression and 
severe respiratory signs of disease following challenge, shed high titers of virus 
in their upper and lower airways, and lesions of consolidation covered an 
average of 48% of their lungs at post-mortem. 
In contrast, calves immunized with ∆SHrBRSV were almost completely 
protected following challenge, and showed only very mild signs of respiratory 
disease, shed only minimal or no virus in the upper and lower airways, and 
demonstrated minimal inflammation in the lungs at post-mortem. These results 
confirm findings in young (1-4 weeks old) seronegative calves, immunized 
with the same vaccine, and challenged with BRSV six months later (Taylor et 
al. 2014b), and extend findings to apply to young calves with specific MDA. 
No immune responses were detected in ∆SHrBRSV-immunized calves 
before challenge, and the very high level of protection observed following 
challenge appears to have been mediated by strong anamnestic responses, both 
humoral and cellular, indicating that vaccination had primed immune memory 
sufficient to induce protection against BRSV five weeks later. 
The rapid anamnestic responses of mucosal BRSV-specific IgA antibodies 
and neutralizing antibodies directed against the F and G proteins in serum, 
observed in ∆SHrBRSV-immunized calves, were in agreement with                     
- 
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observations in BRSV-ISCOM-immunized calves (paper I, paper II and 
Hägglund et al. 2004), and have previously been associated with protection 
(Kimman, Westenbrink, Schreuder, et al. 1987; Kimman, Westenbrink, et al. 
1989; Ellis et al. 2007; Taylor et al. 1997). 
Local ∆SHrBRSV-induced T cell memory in the airways was observed 
following isolation and BRSV restimulation of lymphocytes from 
tracheobronchial lymph nodes on PID 7, characterized by IFNγ rather than IL-
4 production, suggesting a Th1-biased response. Corresponding analysis was 
not performed in subunit-immunized calves, due to logistical limitations. 
However, a previous study demonstrated N nanoring-specific proliferation and 
IFNγ production in lymphocytes isolated from tracheobronchial lymph nodes 
twenty days after challenge from calves immunized intranasally and 
intramuscularly with N nanorings, but not in calves immunized intramuscularly 
alone (Riffault et al. 2010). 
SUMont-vaccinated calves were also protected following challenge, 
although significantly less protected than ∆SHrBRSV-immunized calves: with 
more severe clinical signs and virus shedding, and more inflammation in the 
lungs. 
The good level of protection induced by SUMont vaccination appears to 
have been mainly mediated by cellular responses against the internal proteins 
included in the subunit composition: N, M2-1 and P. 
Humoral responses were detectable already after first vaccination, but these 
were non-neutralizing and directed against N, M2-1 and P, and not against F 
and G. The BRSV F and G epitopes, recombinantly attached to N nanorings, 
and included in both subunit vaccines, were selected based on their ability to 
induce protective antibodies (Arbiza et al. 1992; Bastien et al. 1997; Thomas et 
al. 1998; Chargelegue et al. 1998; Wu et al. 2007), and have no known T cell 
epitopes in cattle (Fogg et al. 2001). Therefore, the protection observed in 
SUMont-immunized calves was likely mainly mediated by T cell responses 
against N, P and M2-1, whereas the F and G epitopes had no or a very limited 
impact.  
HRSV proteins N, P or M2-1 in SUMont induced cross-reactive responses 
to restimulation with BRSV of circulating T cells, isolated after both first and 
second SUMont vaccination, and induced protection following challenge 
which exceeded the partial protection observed by Riffault et al., following 
immunization of calves with HRSV N nanorings alone (Riffault et al. 2010). 
Proteins N, P and M2-1 are all highly conserved between BRSV and HRSV 
(Samal et al. 1991; Mallipeddi & Samal 1992; Zamora & Samal 1992), and 
contain CD8+ T cell epitopes in cattle (Gaddum et al. 2003). In contrast to 
SUMont, SUAbis failed to induce detectable T cell responses, and 
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consequently afforded immunized calves only limited protection following 
challenge. 
The distinct degrees of protection afforded by the three vaccines can be 
explained by differences in the immune responses they induced. This in turn 
might be explained by differences in type of antigen (live/subunit), antigen 
quantity, adjuvant, as well as route and number of administrations. 
Replication of ∆SHrBRSV in the airways of immunized calves and the 
subsequent expression of native viral proteins and replication of viral RNA in 
infected cells would have primed several humoral and cellular immunological 
pathways, as discussed below, although only very limited replication of 
vaccine virus was detected in ∆SHrBRSV-immunized calves. 
SUMont contained relatively high amounts of recombinant HRSV N, P and 
M2-1 proteins, and induced cross-reactive immune responses, which would 
likely be difficult to achieve through inoculation with live HRSV, considering 
the poor replication of HRSV in calves (Thomas et al. 1984). Thus, SUMont 
overcame the BRSV/HRSV host species barrier, by administration of sufficient 
amount of appropriate HRSV antigen, in conjunction with a water-in-oil 
adjuvant. 
Pre-existing BRSV-specific MDA did not suppress either humoral or 
cellular immune responses to SUMont vaccination. ∆SHrBRSV-immunized 
calves failed to seroconvert following vaccination, which is in contrast to that 
previously observed in calves with low levels of serum specific MDA (Taylor 
et al. 2014b), suggesting suppression of antibody production by serum MDA. 
On the other hand, the rapid anamnestic responses upon BRSV challenge 
observed in ∆SHrBRSV-immunized calves, indicate very good priming, 
despite moderate levels of serum specific MDA. 
Antibody characteristics in these vaccine-induced humoral responses 
varied. Whereas humoral responses induced by ∆SHrBRSV were neutralizing, 
and likely induced by the F and G proteins on the surface of the vaccine virus, 
antibodies detected in calves vaccinated with SUMont or SUAbis were non-
neutralizing, and were instead directed against the internal viral proteins N, P 
and M2-1. Serum and mucosal antibodies against proteins F and G have been 
shown to be protective through virus neutralization (Westenbrink et al. 1989; 
Walsh et al. 1987; Taylor et al. 1997; Taylor et al. 2005), whereas antibodies 
against N, P and M2-1 are less likely to contribute to protection, as these are 
internal viral proteins. However, the roles of these antibodies in the SUMont 
observed protection require further investigation. 
Lack of immunogenicity of the BRSV F and G epitopes (attached to N 
nanorings) might be related to epitope conformation or accessibility in these 
constructs, even though the protein products of all constructs were verified by 
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epitope-specific monoclonal antibody ELISAs (data not shown). The lack of 
immunogenicity might also be explained by an insufficient exposure of these 
epitopes, which might be resolved by increasing the administered dose, or by 
increasing the number of F and G epitopes attached to N nanorings (Hervé et 
al. 2014). 
Both ∆SHrBRSV and SUMont induced a local or systemic Th1-oriented 
CD4+ T lymphocyte response. BRSV-specific T cells producing IFNγ were 
detected in PBMCs from SUMont-immunized calves after a single vaccination, 
and in tracheobronchial lymph node cells from ∆SHrBRSV-immunized calves 
after challenge. Due to logistical limitations, priming of T cell responses in 
circulating PBMCs was not analyzed after challenge, and only in 
tracheobronchial lymph node cells from ∆SHrBRSV-immunized calves and 
controls. Therefore, local priming of T cell responses by SUMont, and 
circulating T cells primed by ∆SHrBRSV, cannot be excluded. As discussed 
earlier, a strong and balanced CD4+ T helper cell response is important to 
enhance antibody production, cytolytic activity, and immune memory (Taylor 
et al. 1995; Clarke 2000; Amanna & Slifka 2010). 
The contribution of cytolytic CD8+ T cells was not confirmed herein, but 
these can be expected to have been activated by ∆SHrBRSV and SUMont, 
since both contained antigens with epitopes recognized by CD8+ CTLs and, 
based on studies in vitro, both were suggested to induce the proliferation of 
IFNγ producing CD4+ T helper cells, which would have stimulated activation 
of CTLs. Furthermore, replication of ∆SHrBRSV in host cells is likely to have 
activated antigen specific CTLs, following presentation of vaccine antigen on 
MHC class I molecules, and induction of relevant cytokine production 
(Masopust et al. 2007). SUMont may have activated BRSV cross-protective 
CTLs through cross presentation by APCs (Bevan 2006), or after adjuvant-
mediated ingression into the cytoplasm of host cells (Rao & Alving 2000). 
Confirmation of induction of CTLs by ∆SHrBRSV and SUMont could be 
obtained by use of a specific CD8+ T cell cytolytic activity assay, as discussed 
for BRSV-ISCOMs, and should be investigated in future studies. 
Route of immunization likely also affected the degree of vaccine-induced 
protection. For live virus vaccines, the intranasal route has been shown to be 
more effective than parenteral routes in overcoming the suppressive effect of 
specific MDA, and inducing protective immunity (Kimman, Westenbrink, et 
al. 1989; Kimman, Westenbrink, Schreuder, et al. 1987; Vangeel et al. 2007), 
perhaps by activating antigen-specific memory lymphocytes in the mucosa 
with appropriate homing signals (Belyakov & Ahlers 2009). This is consistent 
with the strong local immune responses observed in ∆SHrBRSV-immunized 
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calves. However, immunity induced by mucosal live BRSV vaccination may 
have limited duration (Ellis et al. 2013). 
SUMont on the other hand, appear suitable for intramuscular administration 
in calves. When N nanorings alone were administered to calves intranasally 
and intramuscularly, or intramuscularly alone, both regimens afforded 
similarly partial protection in a challenge with moderate clinical expression 
(Riffault et al. 2010). The enhanced protection induced by SUMont (in a severe 
challenge), compared to N nanorings alone, is likely attributable to the addition 
of HRSV proteins P and M2-1. 
SUAbis induced limited protection when administered subcutaneously, but 
to the author’s knowledge, there is no literature to suggest that the 
subcutaneous route is inherently unfavorable in cattle. Studies using 
subcutaneous administration of recombinant protein formulated with AbISCO-
300 have successfully induced both humoral and cellular immune responses: 
immunization of cattle with recombinant bluetongue proteins, adjuvanted by 
AbISCO-300, induced neutralizing antibodies against the surface protein VP2, 
NS1- and NS2-specific T cell responses, and protection of cattle against 
bluetongue infection (Anderson et al. 2013; Anderson et al. 2014). Thus, the 
lack of immunogenicity of SUAbis is more likely due a sub-optimal 
combination of adjuvant and antigen, rather than to route of administration. 
The two adjuvants used to formulate the subunit vaccines are reported to be 
capable of inducing similar immune responses, albeit through different modes 
of action (Lövgren Bengtsson et al. 2011; Aucouturier et al. 2001), which may 
also partially explain the difference in immunogenicity. 
SUAbis was adjuvanted by AbISCO-300, which are reported to have 
similar adjuvant effects to that of classic ISCOMs, as discussed earlier 
(Lövgren Bengtsson et al. 2011), although these effects are likely enhanced by 
various degrees of antigen incorporation into classic ISCOMs. The 
immunogenicity of SUAbis would likely be improved by the addition of a full-
length BRSV membrane protein, which is more apt to associate with ISCOMs, 
and may also promote uptake of ISCOM/antigen complexes by APCs (Lövgren 
Bengtsson et al. 2011; Villacres et al. 1998). The BRSV F protein may be a 
good candidate, as this protein was abundant in BRSV-ISCOMs (paper II). 
SUMont contained Montanide ISA71VG as adjuvant, a water-in-oil 
emulsion. The adjuvanting effects of emulsions are mediated through induction 
of general inflammation; presentation of antigen at the water-oil interface; 
enhancing cell internalization of antigen; as well as a depot effect (Aikawa et 
al. 1998; Aucouturier et al. 2001). SUMont induced a Th1-oriented T cell 
response, which is in agreement with previous studies using the same and 
similar adjuvants, as reviewed by Heegaard et al. (Heegaard et al. 2011), and 
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which probably largely explains the good level of protection observed in 
SUMont-immunized calves. 
Therefore, Montanide ISA71VG appeared more suitable than AbISCO-300 
to adjuvant the subunit composition in paper IV, although the addition of full-
length BRSV glycoproteins to the subunit composition might reverse this. 
None of the subunit vaccines caused more than limited local and systemic 
adverse reactions following parenteral immunization, and live ∆SHrBRSV 
induced only nominal clinical signs in some individuals, following intranasal 
immunization. Furthermore, no exacerbation of clinical or histopathological 
disease was observed following challenge.  
Transmission of ∆SHrBRSV to co-housed seronegative sentinel calves was 
excluded in paper IV. However, calves immunized with ∆SHrBRSV in paper 
IV had moderate levels of serum specific MDA and shed only marginal 
amounts of virus after vaccination. When calves with low levels of specific 
MDA were inoculated with either ∆SHrBRSV or wild-type recombinant 
BRSV, both groups shed comparable amounts of virus detected in nasal 
secretion (Taylor et al. 2014b). Further studies are needed to investigate the 
potential transmission of ∆SHrBRSV under field-like conditions, where 
vaccinated calves, with serum specific MDA titers ranging from none to high, 
are co-housed with seronegative animals. 
Attenuation of the ∆SHrBRSV vaccine virus relies solely on gene deletion, 
which makes it more refractory to wild-type reversion, compared to live virus 
vaccines in which attenuation, fully or in part, rely on point mutations (Lin et 
al. 2006). However, although the risk that ∆SHrBRSV regains the SH gene 
might be considered negligible, there is also the remote possibility that 
recombinantly introduced intergenic sequences are transferred to BRSV field 
strains during co-infections (Spann et al. 2003). This highlights the need for 
further studies on the extent of viral shedding and transmission following 
∆SHrBRSV immunization, and warrants investigations on the specific risk of 
genetic recombination between ∆SHrBRSV and BRSV field strains. 
 
In conclusion, vaccines can induce protection against BRSV-infection 
through induction of several types of immune responses, which may be 
influenced by vaccine-composition, administration route and immunization 
regimen, as well as factors in the host, including level of specific MDA. 
Despite undetectable immune responses before challenge, a single 
intranasal immunization with ∆SHrBRSV primed local T cells, as well as rapid 
production of neutralizing systemic and mucosal IgA antibodies following 
challenge five weeks later, and afforded calves almost complete protection in a 
severe challenge. 
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The good protection afforded by SUMont immunization was likely 
mediated through HRSV N, P and M2-1 specific T cell cross-reactive 
responses to corresponding BRSV proteins. Non-neutralizing antibodies 
induced by SUMont were directed against the internal proteins N, P and M2-1, 
and not against the BRSV F and G epitopes grafted onto N nanorings.  
Further studies are required to investigate the duration of protective immune 
response induced by ∆SHrBRSV and SUMont. Priming and boosting using 
heterologous vaccines or routes are increasingly used to improve the duration 
of immunity (Blanco et al. 2014; Grunwald et al. 2014; ClinicalTrials.gov id 
NCT01805921), and is under evaluation using ∆SHrBRSV and a modified 
SUMont vaccine. 
The DIVA characteristics of ∆SHrBRSV and SUMont need further 
investigation, through prolonged seromonitoring of vaccinated and sentinel 
animals that are exposed to BRSV, to ascertain that contagious animals 
develop anti-SH antibodies, and that animals with sufficient virological 
protection do not. Using the DIVA property, seromonitoring of calves and 
older animals in vaccinated herds could be used to detect changes in vaccine 
safety and efficacy, and outbreaks of BRSV despite vaccination. Detecting 
isotypes other than IgG1 might circumvent the masking effect of MDA, when 
detecting anti-SH antibodies in a DIVA assay.  
5.5 Thesis Summary and Conclusions 
 
This thesis work started out with the evaluation of BRSV-ISCOMs, which 
induced strong humoral responses and a Th1-oriented T cell response in young 
calves with specific MDA, afforded calves with a high level of clinical and 
virological protection, and was suggested to be safe. 
The protein content of BRSV-ISCOMs was characterized, and the immune 
responses in immunized calves were further investigated, to enable 
standardization of the formulation, and to facilitate formulation of a new 
vaccine using recombinant proteins, either classic ISCOMs or with mixed-in 
adjuvant. Protein content characterization identified BRSV proteins F, N, G, 
M, P, M2-1 and SH in BRSV-ISCOMs, and demonstrated that proteins F and 
N constituted approximately half of the protein content, with ~77 µg of F and 
~17 µg of N per dose of BRSV-ISCOMs. 
A BRSV calf infection model was refined and characterized, to facilitate the 
evaluation of the two subunit vaccines and the live recombinant vaccine. This 
BRSV infection model proved to be robust, with high clinical expression in 
calves with passive immunity.  
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Two recombinant subunit vaccines were designed, consisting of HRSV 
proteins N, P and M2-1, and epitopes from BRSV F and G, adjuvanted with 
ISCOMs matrices, AbISCO-300 (SUAbis) and the Montanide oil emulsion 
(SUMont), respectively, and were evaluated along with the live recombinant 
vaccine BRSV, ∆SHrBRSV. 
∆SHrBRSV induced almost complete clinical and virological protection, 
whereas SUMont immunization induced a high level of protection following 
challenge in the severe model. ∆SHrBRSV and SUMont appear to achieve this 
level of protective immunity through activation of different immunological 
pathways. ∆SHrBRSV-induced protection relied mainly on induction of 
neutralizing antibodies directed against viral surface protein, and local T cell 
responses in the airways. SUMont-induced protection appears to have been 
mainly mediated by circulating T cells, which were likely activated by HRSV 
N, P or M2-1 protein in the vaccine, but cross-reacted with corresponding 
BRSV protein. 
Effective immunity in young calves depends on a strong and balanced 
immune response, which might be achieved by activating multiple arms of the 
immune system, by combining antigens that induce humoral and cellular 
immune response, and through appropriate adjuvant immunomodulation. Rapid 
and long lasting immunity in young calves might be accomplished by 
combining the rapid response induced by mucosal immunization, also shown to 
be less inhibited by maternal antibodies, with heterologous parenteral boosting, 
which may induce longer lasting immunity. 
Although duration of immune responses was not investigated in this thesis, 
∆SHrBRSV and SUMont may form a suitable base for the development of a 
BRSV vaccination regimen, alone or in combination, which could provide long 
lasting protective immunity in young calves with maternal serum antibodies. In 
addition, the DIVA characteristics of these vaccine candidates need further 
investigation. 
At the time of writing, investigations are ongoing to evaluate the effect on 
duration of protective immunity from heterologous priming with ∆SHrBRSV, 
and boosting with a modified SUMont vaccine (without BRSV epitopes), 
compared to ∆SHrBRSV priming alone or with homologous boosting 
(Makabi-Panzu et al. 2014). That study will also investigate vaccine T cell 
priming in more detail, including priming of CD8+ T cells, through the use of 
MHC-defined calves. 
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6 Future prospects 
The challenge to develop safe and effective vaccines against respiratory 
syncytial virus infection early in life has resulted in considerable advances in 
vaccinology and in the understanding of both BRSV and HRSV. However, 
apart from the practical goal of safe and effective vaccines, there are also many 
aspects about these viruses and the virus/host interaction that need to be 
elucidated further. 
For instance, the identification of a universal pre-infection immunological 
correlate of protection from BRSV infection could substitute calf infections 
when evaluating BRSV vaccines, and could in addition be used in the field to 
monitor expected vaccine-induced protection. Although pre-infection systemic 
and local neutralizing antibodies, as well as RSV specific T cells have 
individually been associated with protection, these cannot be used to predict 
the degree of protection following infection. The quest for a vaccine-induced 
balanced immune response will likely also require an aggregate correlate of 
protection, including several immunological factors. 
I believe this quest must also involve further refinement of the methods 
used to investigate conventional immunological parameters, such as measuring 
CD8+ T cell specific cytotoxic activity and B cell specific expansion after ex 
vivo restimulation, combined with flow cytometric analysis of mucosal homing 
markers. Furthermore, as in vitro virus neutralizing capacity of sera do not 
correlate with protection, and do not account for non-neutralizing protective 
antibodies (e.g. antibodies against the SH proteins), new ways to estimate the 
in vivo effectiveness of antibodies needs to be developed, and may entail a 
combination of several epitope-specific avidity ELISAs (such as a modified 
mAb 19 competitive ELISA). However, and more importantly, there are likely 
also factors in the bovine immune response and generation of immune memory 
to BRSV that we are not yet aware of, which may best be investigated by 
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hypotheses-generating in vitro and in vivo studies using transcriptomics and 
proteomics. 
 
Another factor restricting BRSV research and the evaluation of new vaccine 
candidates has been the lack of a reproducible infection model, with field-like 
clinical signs and pathology in calves with passive BRSV-specific immunity. 
Similarly for HRSV, small animal models do not mimic disease seen in infants. 
The BRSV calf infection model and tools for post-infection monitoring 
presented in this thesis can serve as a solid foundation for future BRSV 
research, and certain aspects may be extrapolated to pathogenesis and immune 
responses in human infants infected with HRSV. Moreover, post-infection 
monitoring could be made even less subjective through incorporation of novel 
quantitative technology, such as: automated quantification of calf feed intake 
and activity; more accurate quantification and localization of lung lesions post-
mortem using computed tomography; and improvement of pulmonary function 
measurements such as the forced oscillation technique in calves. 
 
Nonetheless, the infection models used in this thesis work clearly 
demonstrated protective efficacy of three vaccine candidates: BRSV-ISCOMs, 
∆SHrBRSV and SUMont. 
BRSV-ISCOMs induced a high level of protection in calves with maternal 
antibodies, but would be difficult to produce consistently in commercial 
quantities, and have not been shown to be DIVA-compatible. On the other 
hand, classic ISCOMs produced using a recombinant deleted gene BRSV (e.g. 
∆SHrBRSV, which can be propagated in high titers), would be DIVA-
compatible. However, a recombinant subunit approach, using BRSV (or 
HRSV) proteins, in proportions identified in BRSV-ISCOMs, might better 
facilitate batch-to-batch consistency, potentially increase the vaccine purity and 
decrease production costs, as well as permit DIVA compatibility. 
 
The recombinant subunit composition evaluated in this thesis work, using a 
subset of the proteins identified in BRSV-ISCOMs, induced a good level of 
protection in a severe challenge model, when adjuvanted by an oil emulsion 
(SUMont), which was mainly mediated by T cell responses directed against the 
internal HRSV proteins N, P and M2-1, and not the BRSV F and G epitopes. 
The individual roles of the N, P and M2-1 proteins, and whether they are 
essential to attain the level of protection observed in this thesis wok, should be 
further investigated, and the subunit composition optimized regarding their 
individual quantities. The addition to the subunit composition of recombinant 
antigens that could induce neutralizing antibodies, would likely enhance 
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induced protection; particularly considering that SUMont immunization 
induced production of mucosal IgA antibodies, which would likely be effective 
if they were directed against viral surface proteins. For this purpose the fusion 
protein F, in full length, is a good candidate, as this protein is highly conserved 
between strains of BRSV, and between BRSV and HRSV (Valarcher et al. 
2000), and may provide protection against a wide range of BRSV strains 
circulating in the field. In addition, the F protein contains epitopes recognized 
by bovine CD8+ T cells and was abundant in BRSV-ISCOMs, which in turn 
were highly protective. Work to produce full-length recombinant BRSV or 
HRSV F proteins is currently ongoing, but outside the scope of this thesis 
work. 
 
After optimization, a modified subunit composition might be better 
adjuvanted by a stable oil-in-water emulsion (Richards et al. 2004) or a water-
in-oil-in-water emulsion (Dar et al. 2013), possibly in conjunction with TLR-
agonists, to further enhance innate immune responses and promote maturation 
of antibodies (Delgado et al. 2009). On the other hand, if the optimized subunit 
composition contains only recombinant HRSV proteins, an oil-in-water 
emulsion licensed for use in children (Vesikari et al. 2011) would also be 
interesting to evaluate. Regardless of the final composition of subunits and 
adjuvant, this recombinant protein approach will require further safety 
evaluation before being ready for field evaluation. 
 
∆SHrBRSV, on the other hand, is almost ready for field evaluation. 
∆SHrBRSV has been shown to be sufficiently clinically attenuated in calves 
with levels of serum specific MDA ranging from none to moderate (Taylor et 
al. 2014a; paper IV). However, although ∆SHrBRSV did not transmit to co-
housed seronegative sentinel calves when calves with moderate levels of serum 
specific MDA were intranasally immunized in this thesis work (paper IV), 
gnotobiotic calves and calves with low levels of serum specific MDA shed 
vaccine virus in nasal secretion following combined intranasal/intratracheal 
immunization (Taylor et al. 2014a). Therefore, the only remaining concern, 
which needs further investigation, is whether conventional calves with varying 
levels of specific MDA would shed and transmit this genetically modified virus 
in the field following intranasal immunization. 
∆SHrBRSV could be very useful in the field, by inducing early acquired 
immunity in young calves with specific MDA, as demonstrated in this thesis 
work. However, intranasal immunization with a live vaccine may not provide 
long lasting immunity (Ellis et al. 2013), and homologous intranasal boosting 
might be less effective than boosting by a different route, or using a different 
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vaccine. For example, when calves with specific MDA were immunized 
intranasally with ∆SHrBRSV, either one or two times (with four weeks 
interval), and subsequently challenged with virulent BRSV eleven weeks after 
first vaccination, both groups shed similar amounts of virus in nasal secretion 
(Makabi-Panzu et al. 2014). In the same study, calves primed intranasally with 
∆SHrBRSV and boosted intramuscularly with a reduced SUMont vaccine 
(only N, P and M2-1) shed less virus in nasal secretion following challenge, 
compared to calves only immunized with ∆SHrBRSV (one or two times) 
(Makabi-Panzu et al. 2014). 
Therefore, a heterologous prime/boost regimen, using intramuscular 
boosting with ∆SHrBRSV or an optimized subunit formulation (with full-
length protein F) might be more effective in providing long lasting sterilizing 
immunity, and should be investigated in future studies. Specifically, future 
evaluation studies of ∆SHrBRSV (i.n. + i.m.), an optimized subunit vaccine 
(i.m. + i.m.), or a heterologous prime/boost regimen should investigate post-
vaccination and pre-infection correlates of protection (as previously 
mentioned), degree and duration of protection induced by each regimen, as 
well as safety of each regimen. 
 
In addition, the usefulness of ∆SHrBRSV and an optimized subunit 
composition not including the SH protein (or a combined regimen) as DIVA 
vaccines need to be evaluated in prolonged serological studies of immunized 
and subsequently infected animals, with varying levels of passive immunity, to 
evaluate the ability of these vaccines to avert virus replication and prevent 
induction of anti-SH antibodies when vaccinated animals are exposed to the 
virus. If vaccine-induced virological protection fails, due to genetic changes in 
the virus or due to waning immunity in vaccinated animals, and animals 
become contagious, rising titers of anti-SH antibodies should indicate this. 
 
Finally, an anti-SH antibody DIVA assay, able to identify significant anti-
SH seroconversions in vaccinated animals and herds, needs to be validated. To 
avoid detection of colostrum-derived anti-SH antibodies in samples from 
calves, such an assay could detect antibody isotypes other than IgG1, or herd 
seromonitoring could focus on older calves and heifers. In conjunction with 
other control measures, these DIVA vaccines and companion DIVA assay 
could be used to establish BRSV-free regions or herds, while simultaneously 
protecting unexposed animals and herds, with maintained ability to 
serologically monitor virus circulation as well as vaccine efficacy and safety. 
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